<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JAMA Netw Open</journal-id><journal-id journal-id-type="iso-abbrev">JAMA Netw Open</journal-id><journal-id journal-id-type="pmc-domain-id">3211</journal-id><journal-id journal-id-type="pmc-domain">jamasd</journal-id><journal-title-group><journal-title>JAMA Network Open</journal-title></journal-title-group><issn pub-type="epub">2574-3805</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>JAMA Network</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10098970</article-id><article-id pub-id-type="pmcid-ver">PMC10098970.1</article-id><article-id pub-id-type="pmcaid">10098970</article-id><article-id pub-id-type="pmcaiid">10098970</article-id><article-id pub-id-type="pmid">37043198</article-id><article-id pub-id-type="doi">10.1001/jamanetworkopen.2023.7888</article-id><article-id pub-id-type="publisher-id">zoi230256</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="category" specific-use="electronic"><subject>Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group><subj-group subj-group-type="online-only"><subject>Online Only</subject></subj-group><subj-group subj-group-type="subject-area"><subject>Substance Use and Addiction</subject></subj-group></article-categories><title-group><article-title>Estimated Clinical Outcomes and Cost-effectiveness Associated With Provision of Addiction Treatment in US Primary Care Clinics</article-title><alt-title alt-title-type="headline">Clinical Outcomes and Cost-effectiveness Associated With Addiction Treatment</alt-title><alt-title alt-title-type="running-head">Clinical Outcomes and Cost-effectiveness Associated With Addiction Treatment</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Jawa</surname><given-names initials="R">Raagini</given-names></name><degrees>MD</degrees><degrees>MPH</degrees><xref rid="zoi230256aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tin</surname><given-names initials="Y">Yjuliana</given-names></name><degrees>BA</degrees><xref rid="zoi230256aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nall</surname><given-names initials="S">Samantha</given-names></name><degrees>MPH</degrees><xref rid="zoi230256aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Calcaterra</surname><given-names initials="SL">Susan L.</given-names></name><degrees>MD</degrees><degrees>MPH</degrees><degrees>MS</degrees><xref rid="zoi230256aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Savinkina</surname><given-names initials="A">Alexandra</given-names></name><degrees>MSPH</degrees><xref rid="zoi230256aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Marks</surname><given-names initials="LR">Laura R.</given-names></name><degrees>MD</degrees><degrees>PhD</degrees><xref rid="zoi230256aff6" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kimmel</surname><given-names initials="SD">Simeon D.</given-names></name><degrees>MD</degrees><degrees>MA</degrees><xref rid="zoi230256aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="zoi230256aff7" ref-type="aff">
<sup>7</sup>
</xref><xref rid="zoi230256aff8" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Linas</surname><given-names initials="BP">Benjamin P.</given-names></name><degrees>MD</degrees><degrees>MPH</degrees><xref rid="zoi230256aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="zoi230256aff8" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Barocas</surname><given-names initials="JA">Joshua A.</given-names></name><degrees>MD</degrees><xref rid="zoi230256aff9" ref-type="aff">
<sup>9</sup>
</xref></contrib></contrib-group><aff id="zoi230256aff1"><label>1</label>Section of General Internal Medicine, Center for Research on Healthcare, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania</aff><aff id="zoi230256aff2"><label>2</label>Section of Infectious Diseases, Boston Medical Center, Boston, Massachusetts</aff><aff id="zoi230256aff3"><label>3</label>Division of General Internal Medicine, University of Colorado Anschutz Medical Campus, Aurora</aff><aff id="zoi230256aff4"><label>4</label>Division of Hospital Medicine, University of Colorado Anschutz Medical Campus, Aurora</aff><aff id="zoi230256aff5"><label>5</label>Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut</aff><aff id="zoi230256aff6"><label>6</label>Division of Infectious Diseases, School of Medicine, Washington University in St Louis, Missouri</aff><aff id="zoi230256aff7"><label>7</label>Section of General Internal Medicine, Boston Medical Center, Boston, Massachusetts</aff><aff id="zoi230256aff8"><label>8</label>Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts</aff><aff id="zoi230256aff9"><label>9</label>Divisions of General Internal Medicine and Infectious Diseases, University of Colorado Anschutz Medical Campus, Aurora</aff><author-notes><title>Article Information</title><p><bold>Accepted for Publication:</bold> February 28, 2023.</p><p content-type="published-online"><bold>Published:</bold> April 12, 2023. doi:<uri content-type="doi">10.1001/jamanetworkopen.2023.7888</uri></p><p content-type="open-access-note"><bold>Open Access:</bold> This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://jamanetwork.com/pages/cc-by-license-permissions" ext-link-type="uri">CC-BY License</ext-link>. &#169; 2023 Jawa R et al. <italic toggle="yes">JAMA Network Open</italic>.</p><corresp id="zoi230256cor1"><bold>Corresponding Author:</bold> Joshua A. Barocas, MD, Divisions of General Internal Medicine and Infectious Diseases, University of Colorado Anschutz Medical Campus, 12631 E 17th Ave, Eighth Floor, Academic Office 1, Mail Stop B180, Aurora, CO 80045 (<email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="joshua.barocas@anschutz.edu">joshua.barocas@anschutz.edu</email>).</corresp><p content-type="author-contributions"><bold>Author Contributions:</bold> Mr Tin and Dr Barocas had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.</p><p><italic toggle="yes">Concept and design:</italic> Jawa, Tin, Nall, Calcaterra, Savinkina, Marks, Kimmel, Barocas.</p><p><italic toggle="yes">Acquisition, analysis, or interpretation of data:</italic> Jawa, Tin, Nall, Calcaterra, Marks, Kimmel, Linas, Barocas.</p><p><italic toggle="yes">Drafting of the manuscript:</italic> Jawa, Tin, Nall, Calcaterra, Marks, Barocas.</p><p><italic toggle="yes">Critical revision of the manuscript for important intellectual content:</italic> Jawa, Tin, Nall, Savinkina, Marks, Kimmel, Linas, Barocas.</p><p><italic toggle="yes">Statistical analysis:</italic> Jawa, Tin, Nall, Savinkina, Marks, Linas, Barocas.</p><p><italic toggle="yes">Obtained funding:</italic> Barocas.</p><p><italic toggle="yes">Administrative, technical, or material support:</italic> Jawa, Tin, Nall, Linas.</p><p><italic toggle="yes">Supervision:</italic> Linas.</p><p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Kimmel reported receiving personal fees from Massachusetts Department of Public Health, Bureau of Substance Addiction Services Overdose Education and Prevention Program, and American Academy of Addiction Psychiatry, Opioid Response Network for harm reduction education outside the submitted work and previous consulting with Abt Associates on a Massachusetts Department of Public Health&#8211;funded project to improve access to medications for opioid use disorder treatment. No other disclosures were reported.</p><p content-type="funding-statement"><bold>Funding/Support:</bold> This work was supported by grants K01DA051684 (Dr Barocas), DP2DA051864 (Dr Barocas), K08DA049905-03 (Dr Calcaterra), R25DA033211 (Dr Calcaterra), K12DA050607 (Dr Calcaterra), R01DA046527 (Dr Linas), and K23DA054363 (Dr Kimmel) from the National Institute of Drug Abuse and grant T32AI052074 from the National Institute of Allergy and Infectious Diseases (Dr Jawa).</p><p><bold>Role of the Funder/Sponsor:</bold> The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p><p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-ZOI230256-1-s" ref-type="supplementary-material">Supplement 2</xref>.</p></author-notes><pub-date pub-type="epub" iso-8601-date="2023-04-12T10:00"><day>12</day><month>4</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2023</year></pub-date><volume>6</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">433427</issue-id><elocation-id>e237888</elocation-id><history><date date-type="received"><day>16</day><month>10</month><year>2022</year></date><date date-type="accepted"><day>28</day><month>2</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>12</day><month>04</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>14</day><month>04</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-15 20:25:44.597"><day>15</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright 2023 Jawa R et al. <italic toggle="yes">JAMA Network Open</italic>.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the CC-BY License.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jamanetwopen-e237888.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf-version" xlink:href="jamanetwopen-e237888.pdf">jamanetwopen-e237888.pdf</self-uri><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="silverchair" xlink:href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2023.7888"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="correction-forward" xml:lang="en" xlink:title="correction" vol="6" journal-id="JAMA Netw Open" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC10176116"><article-title>Error in Table 3</article-title><volume>6</volume><issue>5</issue><date><day>11</day><month>5</month><year>2023</year></date><elocation-id>e2315795</elocation-id><source>JAMA Network Open</source><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2023.15795</pub-id><pub-id pub-id-type="pmcid">PMC10176116</pub-id><pub-id pub-id-type="pmid">37166806</pub-id></related-article><abstract abstract-type="key-points"><title>Key Points</title><sec id="ab-zoi230256-1"><title>Question</title><p>What are the estimated clinical outcomes, costs, and cost-effectiveness of integrating buprenorphine and harm reduction kits into primary care for people who inject opioids?</p></sec><sec id="ab-zoi230256-2"><title>Findings</title><p>In this decision analytical model using the Reducing Infections Related to Drug Use Cost-Effectiveness model, integrating buprenorphine alone extended discounted life expectancy by 0.16 years and buprenorphine combined with harm reduction kits extended discounted life expectancy by 0.17 years. Compared with the status quo, buprenorphine and harm reduction kits reduced drug use&#8211;related mortality by 33% and was cost-effective.</p></sec><sec id="ab-zoi230256-3"><title>Meaning</title><p>These findings suggest that integrating buprenorphine and harm reduction kits into primary care may improve clinical outcomes, modestly increase costs, and be cost-effective to health systems.</p></sec></abstract><abstract abstract-type="teaser" specific-use="electronic"><p>This decision analytical model of a simulated representative cohort of people who inject opioids estimates the long-term clinical outcomes, costs, and cost-effectiveness of different strategies of integrating addiction treatment into US primary care.</p></abstract><abstract><sec id="ab-zoi230256-4"><title>Importance</title><p>US primary care practitioners (PCPs) are the largest clinical workforce, but few provide addiction care. Primary care is a practical place to expand addiction services, including buprenorphine and harm reduction kits, yet the clinical outcomes and health care sector costs are unknown.</p></sec><sec id="ab-zoi230256-5"><title>Objective</title><p>To estimate the long-term clinical outcomes, costs, and cost-effectiveness of integrated buprenorphine and harm reduction kits in primary care for people who inject opioids.</p></sec><sec id="ab-zoi230256-6"><title>Design, Setting, and Participants</title><p>In this modeling study, the Reducing Infections Related to Drug Use Cost-Effectiveness (REDUCE) microsimulation model, which tracks serious injection-related infections, overdose, hospitalization, and death, was used to examine the following treatment strategies: (1) PCP services with external referral to addiction care (status quo), (2) PCP services plus onsite buprenorphine prescribing with referral to offsite harm reduction kits (BUP), and (3) PCP services plus onsite buprenorphine prescribing and harm reduction kits (BUP plus HR). Model inputs were derived from clinical trials and observational cohorts, and costs were discounted annually at 3%. The cost-effectiveness was evaluated over a lifetime from the modified health care sector perspective, and sensitivity analyses were performed to address uncertainty. Model simulation began January 1, 2021, and ran for the entire lifetime of the cohort.</p></sec><sec id="ab-zoi230256-7"><title>Main Outcomes and Measures</title><p>Life-years (LYs), hospitalizations, mortality from sequelae (overdose, severe skin and soft tissue infections, and endocarditis), costs, and incremental cost-effectiveness ratios (ICERs).</p></sec><sec id="ab-zoi230256-8"><title>Results</title><p>The simulated cohort included 2.25 million people and reflected the age and gender of US persons who inject opioids. Status quo resulted in 6.56 discounted LYs at a discounted cost of $203&#8201;500 per person (95% credible interval, $203&#8201;000-$222&#8201;000). Each strategy extended discounted life expectancy: BUP by 0.16 years and BUP plus HR by 0.17 years. Compared with status quo, BUP plus HR reduced sequelae-related mortality by 33%. The mean discounted lifetime cost per person of BUP and BUP plus HR were more than that of the status quo strategy. The dominating strategy was BUP plus HR. Compared with status quo, BUP plus HR was cost-effective (ICER, $34&#8201;400 per LY). During a 5-year time horizon, BUP plus HR cost an individual PCP practice approximately $13&#8201;000.</p></sec><sec id="ab-zoi230256-9"><title>Conclusions and Relevance</title><p>This modeling study of integrated addiction service in primary care found improved clinical outcomes and modestly increased costs. The integration of addiction service into primary care practices should be a health care system priority.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="H1-1-ZOI230256"><title>Introduction</title><p>The US opioid epidemic has led to increasing incidence of opioid-related overdose and injection drug use&#8211;related infections, such as infective endocarditis (IE) and severe skin and soft tissue infections (SSTIs).<sup><xref rid="zoi230256r1" ref-type="bibr">1</xref>,<xref rid="zoi230256r2" ref-type="bibr">2</xref></sup> Given the scope of the epidemic, there is a need to rapidly scale up addiction treatment capacity and harm reduction services for opioid use disorder (OUD).</p><p>Primary care practitioners (PCPs) are the largest clinical workforce in the US,<sup><xref rid="zoi230256r3" ref-type="bibr">3</xref></sup> but few provide a full spectrum of addiction care on site.<sup><xref rid="zoi230256r4" ref-type="bibr">4</xref></sup> Primary care practices are a practical place to integrate addiction services, where PCPs can prescribe buprenorphine and deliver harm reduction kits. Although PCPs view buprenorphine as effective,<sup><xref rid="zoi230256r4" ref-type="bibr">4</xref>,<xref rid="zoi230256r5" ref-type="bibr">5</xref>,<xref rid="zoi230256r6" ref-type="bibr">6</xref></sup> prescribing has been slow to increase<sup><xref rid="zoi230256r7" ref-type="bibr">7</xref>,<xref rid="zoi230256r8" ref-type="bibr">8</xref></sup> because of the lack of institutional support,<sup><xref rid="zoi230256r6" ref-type="bibr">6</xref>,<xref rid="zoi230256r9" ref-type="bibr">9</xref></sup> low levels of interest in treating OUD because of perceived burden and other factors,<sup><xref rid="zoi230256r4" ref-type="bibr">4</xref></sup> and the need for additional training.<sup><xref rid="zoi230256r10" ref-type="bibr">10</xref></sup> Recent policy changes that removed mandatory training requirements to obtain a buprenorphine waiver<sup><xref rid="zoi230256r11" ref-type="bibr">11</xref></sup> could improve addiction treatment access for patients in all health care settings, including within primary care, where multidisciplinary and coordinated care delivery models have facilitated buprenorphine prescribing.<sup><xref rid="zoi230256r12" ref-type="bibr">12</xref>,<xref rid="zoi230256r13" ref-type="bibr">13</xref></sup></p><p>Although prescribing medication for OUD (MOUD) is one way to address OUD and prevent complications, not all patients are ready or willing to initiate pharmacologic treatment. In addition, MOUD does not guarantee abstinence, so there is a need for additional strategies to reduce risk. A harm reduction approach can mitigate risk while acknowledging the conditions that may lead individuals to continue to use substances.<sup><xref rid="zoi230256r14" ref-type="bibr">14</xref></sup> Harm reduction strategies include provision of sterile injection equipment, fentanyl test strips, skin cleaning education, overdose education, and naloxone distribution.<sup><xref rid="zoi230256r14" ref-type="bibr">14</xref>,<xref rid="zoi230256r15" ref-type="bibr">15</xref></sup> Given US regional regulations and legal concerns, harm reduction equipment provision is typically offered in non&#8211;health care community settings. However, there is an evolving national priority from the American Rescue Plan to expand access to harm reduction.<sup><xref rid="zoi230256r16" ref-type="bibr">16</xref></sup> Thus, an opportunity exists to colocate these services within primary care, where patients may have existing, trusting relationships with clinicians.<sup><xref rid="zoi230256r17" ref-type="bibr">17</xref></sup></p><p>Although integrating buprenorphine and harm reduction kits into primary care may improve clinical outcomes among people who inject opioids, such a shift could include financial tradeoffs between potential immediate costs. We sought to estimate the long-term clinical outcomes, costs, and cost-effectiveness of different strategies of integrating addiction treatment into US primary care.</p></sec><sec id="H1-2-ZOI230256"><title>Methods</title><sec id="H2-1-ZOI230256"><title>Analytical Overview</title><p>For this decision analytical model, we used a validated Monte Carlo microsimulation model, the Reducing Infection Related to Drug Use Cost-Effectiveness (REDUCE) model, that simulates the natural history of injection opioid use (eMethods in <xref rid="note-ZOI230256-1-s" ref-type="supplementary-material">Supplement 1</xref>). We used the model to compare the following treatment strategies for integrated addiction care in primary care: (1) standard primary care services, where PCPs refer patients to external addiction care (status quo); (2) standard primary care services plus onsite buprenorphine prescribing with referral to offsite harm reduction kits (BUP); and (3) standard primary care services plus onsite buprenorphine prescribing and harm reduction kit provision (BUP plus HR) (<xref rid="zoi230256f1" ref-type="fig">Figure</xref>). In all 3 modeled strategies, we assume that patients begin the simulation not treated with MOUD. We also assume that if patients are hospitalized and not receiving MOUD, they undergo inpatient opioid detoxification and are not given MOUD. If they are already receiving MOUD and are hospitalized, then use of that medication is continued on discharge. Race and ethnicity were not factored into this analysis given limitations of the model and limitations of the data used to populate the model. Model simulation began January 1, 2021, and ran for the entire lifetime of the cohort. The study was approved by the University of Colorado Institutional Review Board, which determined the REDUCE model to be non&#8211;human subject research. The study followed the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) reporting guideline.</p><fig position="float" id="zoi230256f1" fig-type="figure" orientation="portrait"><label>Figure. </label><caption><title>Model Schematic for 3 Strategies Integrating Addiction Care Into Primary Care</title><p>The 3 strategies were (1) primary care practitioner (PCP) services with external referral to addiction care (status quo), (2) PCP services plus onsite buprenorphine prescribing with referral to offsite harm reduction kits (BUP), and (3) PCP services plus onsite buprenorphine prescribing and harm reduction kits (BUP plus HR).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jamanetwopen-e237888-g001.jpg"/></fig><p>In the status quo strategy, patients first link to a PCP and are then referred to, and can link to, an offsite addiction specialist for buprenorphine. Patients can obtain harm reduction kits offsite in the community. In the BUP strategy, once patients link to their PCPs, we assume that buprenorphine can be offered at the time during an office visit, but patients will be referred offsite in the community for harm reduction kits. In the BUP plus HR strategy, buprenorphine is offered and harm reduction kits (consisting of a package of 10 sterile syringes with injection preparation equipment, safer smoking kit, and skin hygiene and wound care supplies) are provided at every office visit; thus, no additional linkage is needed for addiction specialist care or offsite harm reduction kits. The <xref rid="zoi230256f1" ref-type="fig">Figure</xref> outlines the differences among the strategies.</p><p>We used the model to estimate long-term outcomes for the cohort beginning in 2021, including percentage of deaths associated with sequelae, averted hospitalizations, life expectancy (measured in life-years [LYs]), mean lifetime costs per person, and incremental cost-effectiveness ratios (ICERs). We projected lifetime medical costs assuming a health care sector perspective, denominated in 2021 US dollars, and applied a 3% discount rate to both costs and LYs.<sup><xref rid="zoi230256r18" ref-type="bibr">18</xref></sup> We also conducted a 5-year budgetary impact analysis from the perspective of PCP practices to determine the cost of offering BUP plus HR.</p><p>We calculated ICERs of each treatment strategy as the additional cost per person divided by the LYs gained compared with the next less expensive strategy.<sup><xref rid="zoi230256r18" ref-type="bibr">18</xref></sup> We interpreted ICERs using a willingness-to-pay threshold of $100&#8201;000 per LY gained.<sup><xref rid="zoi230256r18" ref-type="bibr">18</xref></sup> We performed deterministic and probabilistic sensitivity analyses to evaluate uncertainty.</p></sec><sec id="H2-2-ZOI230256"><title>REDUCE Model Overview</title><sec id="H3-1-ZOI230256"><title>Model Structure and Simulated Cohort</title><p>The REDUCE model has been described in detail elsewhere.<sup><xref rid="zoi230256r19" ref-type="bibr">19</xref>,<xref rid="zoi230256r20" ref-type="bibr">20</xref>,<xref rid="zoi230256r21" ref-type="bibr">21</xref></sup> Briefly, the model is a closed cohort microsimulation, with no new entrants, of the natural history of injection opioid use, including complications such as overdose, infective endocarditis, and severe SSTI (henceforth referred to as sequelae); treatment; and changes in injection behaviors. The model uses a weekly time step and tracks all individuals from model initiation until death.</p><p>We simulate the cohort stratified by sex, age, and injection behavior profile, which includes injection frequency (high, low, or not currently injecting drugs), sharing of injection equipment, and sterile injection technique.<sup><xref rid="zoi230256r21" ref-type="bibr">21</xref></sup> We assume that initial age, sex, and injection profile does not differ among the strategies. In each strategy, we model adults 18 years or older who predominantly inject opioids and are not taking MOUD at the start of the simulation.</p></sec><sec id="H3-2-ZOI230256"><title>Sequelae of Drug Use and Hospitalization</title><p>Only individuals with injection drug use are at risk of sequelae, and the risk is greater with high-frequency drug use than with low-frequency drug use. Individuals who develop sequelae have a probability of being hospitalized and treated for their condition.<sup><xref rid="zoi230256r22" ref-type="bibr">22</xref>,<xref rid="zoi230256r23" ref-type="bibr">23</xref></sup> To account for the sparsity of addiction consultation service in the US, we assumed that hospitalized individuals did not receive a consultation for addiction care services, underwent opioid withdrawal management with buprenorphine or methadone, and did not continue MOUD use after hospital discharge.<sup><xref rid="zoi230256r24" ref-type="bibr">24</xref>,<xref rid="zoi230256r25" ref-type="bibr">25</xref>,<xref rid="zoi230256r26" ref-type="bibr">26</xref></sup> However, if someone was using MOUD before hospitalization, use of this medication would be continued after hospital discharge. Individuals also have a probability of being discharged against medical advice.</p></sec><sec id="H3-3-ZOI230256"><title>Outpatient Services</title><p>Individuals may link to an outpatient PCP either in the community or after a hospitalization. In the status quo strategy, linkage for individuals who are not taking buprenorphine is first to their PCP with referral to an offsite addiction specialist. If patients present to their addiction specialists, they are offered home-induction buprenorphine, which they can then decide to use. In this strategy, the addiction specialist continues to prescribe buprenorphine until the patient unlinks from care. In both the BUP and BUP plus HR strategies, once a patient links to a PCP, we assume that the PCP has the capacity to initiate and continue to prescribe buprenorphine and that it is offered to all patients who link to care (but not all will accept the offer).<sup><xref rid="zoi230256r27" ref-type="bibr">27</xref></sup> In both the status quo and BUP strategies, we assume that patients are receiving harm reduction kits offsite in the community through a background mechanism. In the BUP plus HR strategy, we assume that naloxone is supplied onsite at the intake visit and that harm reduction kits are provided at every visit.</p></sec><sec id="H3-4-ZOI230256"><title>Mortality</title><p>Individuals face a risk of death from sequelae as well as age- and sex-related causes (ie, competing causes). We derived the probability of a fatal overdose in each week as the product of the probability of having an overdose based on an individual&#8217;s age, sex, injection profile, and the probability of death conditional on having an opioid overdose.</p></sec><sec id="H3-5-ZOI230256"><title>Costs</title><p>Individuals accrue weekly costs related to disease status and service use. The costs of OUD care vary by injection behavior profile, with additional costs assigned to those with higher-frequency use. There are initial and weekly costs of MOUD and age- and sex-stratified costs of health care services that are not attributable to opioid use or sequelae.</p></sec></sec><sec id="H2-3-ZOI230256"><title>Model Data</title><sec id="H3-6-ZOI230256"><title>Simulated Cohorts</title><p><xref rid="zoi230256t1" ref-type="table">Table 1</xref> outlines key input parameters for the base case and comparison strategies.<sup><xref rid="zoi230256r27" ref-type="bibr">27</xref>,<xref rid="zoi230256r51" ref-type="bibr">51</xref>,<xref rid="zoi230256r54" ref-type="bibr">54</xref>,<xref rid="zoi230256r55" ref-type="bibr">55</xref>,<xref rid="zoi230256r56" ref-type="bibr">56</xref>,<xref rid="zoi230256r57" ref-type="bibr">57</xref>,<xref rid="zoi230256r58" ref-type="bibr">58</xref>,<xref rid="zoi230256r59" ref-type="bibr">59</xref>,<xref rid="zoi230256r60" ref-type="bibr">60</xref>,<xref rid="zoi230256r61" ref-type="bibr">61</xref>,<xref rid="zoi230256r62" ref-type="bibr">62</xref>,<xref rid="zoi230256r63" ref-type="bibr">63</xref>,<xref rid="zoi230256r64" ref-type="bibr">64</xref>,<xref rid="zoi230256r65" ref-type="bibr">65</xref>,<xref rid="zoi230256r66" ref-type="bibr">66</xref>,<xref rid="zoi230256r67" ref-type="bibr">67</xref>,<xref rid="zoi230256r68" ref-type="bibr">68</xref>,<xref rid="zoi230256r69" ref-type="bibr">69</xref></sup> We initialized the model with a cohort of individuals reflecting the age and gender of the US population who inject opioids (informed by the US Census and literature).<sup><xref rid="zoi230256r28" ref-type="bibr">28</xref>,<xref rid="zoi230256r29" ref-type="bibr">29</xref>,<xref rid="zoi230256r30" ref-type="bibr">30</xref>,<xref rid="zoi230256r31" ref-type="bibr">31</xref>,<xref rid="zoi230256r32" ref-type="bibr">32</xref>,<xref rid="zoi230256r33" ref-type="bibr">33</xref>,<xref rid="zoi230256r34" ref-type="bibr">34</xref></sup> We chose the largest cohort size of 2.25 million to produce stable model runs. At model initialization, the mean (range) age of the cohort was 44 (18-99) years, 70% were male, 50% had high-frequency injection use, 10% had low-frequency injection use, and 40% had no current injection use.<sup><xref rid="zoi230256r28" ref-type="bibr">28</xref>,<xref rid="zoi230256r29" ref-type="bibr">29</xref>,<xref rid="zoi230256r30" ref-type="bibr">30</xref>,<xref rid="zoi230256r31" ref-type="bibr">31</xref>,<xref rid="zoi230256r32" ref-type="bibr">32</xref>,<xref rid="zoi230256r33" ref-type="bibr">33</xref>,<xref rid="zoi230256r34" ref-type="bibr">34</xref></sup> We assumed imperfect access to harm reduction services so that 66% of the cohort practiced unsterile injection technique and 35% regularly shared injecting equipment.<sup><xref rid="zoi230256r70" ref-type="bibr">70</xref></sup></p><table-wrap position="float" id="zoi230256t1" orientation="portrait"><label>Table 1. </label><caption><title>Estimates for Key Model Parameters to Characterize Outcomes of People Who Inject Drugs During a Lifetime<xref rid="zoi230256t1n1" ref-type="table-fn"><sup>a</sup></xref></title></caption><table frame="hsides" rules="groups"><col width="47.54%" span="1"/><col width="23.18%" span="1"/><col width="29.28%" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Parameter</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Estimate (range)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Source</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Population</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Probability of ever drug use</td><td valign="top" align="left" rowspan="1" colspan="1">100% of cohort ever injected, age and gender mix informed by literature</td><td valign="top" align="left" rowspan="1" colspan="1">Lansky A et al,<sup><xref rid="zoi230256r28" ref-type="bibr">28</xref></sup> 2014; Martin SS et al,<sup><xref rid="zoi230256r29" ref-type="bibr">29</xref></sup> 2017; Degenhardt L et al,<sup><xref rid="zoi230256r30" ref-type="bibr">30</xref></sup> 2017; CDC,<sup><xref rid="zoi230256r31" ref-type="bibr">31</xref></sup> 2018; US Census Bureau,<sup><xref rid="zoi230256r32" ref-type="bibr">32</xref></sup> 2016</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Probability of injection drug use frequency</td><td valign="top" align="left" rowspan="1" colspan="1">Varies by age and sex</td><td valign="top" align="left" rowspan="1" colspan="1">Tan S et al,<sup><xref rid="zoi230256r33" ref-type="bibr">33</xref></sup> 2018; Buresh M et al,<sup><xref rid="zoi230256r34" ref-type="bibr">34</xref></sup> 2019</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Needle-sharing prevalence</td><td valign="top" align="left" rowspan="1" colspan="1">0.35 (0.18-0.70)</td><td valign="top" align="left" rowspan="1" colspan="1">Smith BD et al,<sup><xref rid="zoi230256r35" ref-type="bibr">35</xref></sup> 2013; Abara WE et al,<sup><xref rid="zoi230256r36" ref-type="bibr">36</xref></sup> 2019; Kim NJ et al,<sup><xref rid="zoi230256r37" ref-type="bibr">37</xref></sup> 2015; Asher AK et al,<sup><xref rid="zoi230256r38" ref-type="bibr">38</xref></sup> 2019; Ropelewski LR et al,<sup><xref rid="zoi230256r39" ref-type="bibr">39</xref></sup> 2011</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Sequelae of drug use</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Probability of overdose</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">MDPH,<sup><xref rid="zoi230256r40" ref-type="bibr">40</xref></sup> 2016; MDPH,<sup><xref rid="zoi230256r41" ref-type="bibr">41</xref></sup> 2019; CDC,<sup><xref rid="zoi230256r42" ref-type="bibr">42</xref></sup> 2015; Cedarbaum ER and Banta-Green CJ,<sup><xref rid="zoi230256r43" ref-type="bibr">43</xref></sup> 2016; Hudgins R et al,<sup><xref rid="zoi230256r44" ref-type="bibr">44</xref></sup> 1995; Hser YI et al,<sup><xref rid="zoi230256r45" ref-type="bibr">45</xref></sup> 2017</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Low-frequency drug use</td><td valign="top" align="left" rowspan="1" colspan="1">0.0026 (0.0026-0.0027)</td><td rowspan="2" valign="top" align="left" colspan="1">Hedegaard H et al,<sup><xref rid="zoi230256r46" ref-type="bibr">46</xref></sup> 2018</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> High-frequency drug use</td><td valign="top" align="left" rowspan="1" colspan="1">0.0005 (0.0005-0.0006)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Probability of fatal overdose</td><td valign="top" align="left" rowspan="1" colspan="1">0.1100 (0.1000-0.2200)</td><td valign="top" align="left" rowspan="1" colspan="1">Hedegaard H et al,<sup><xref rid="zoi230256r46" ref-type="bibr">46</xref></sup> 2018; MDPH,<sup><xref rid="zoi230256r47" ref-type="bibr">47</xref></sup> 2017; MDPH,<sup><xref rid="zoi230256r48" ref-type="bibr">48</xref></sup> 2019</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Proportion of infections attributable to IE</td><td valign="top" align="left" rowspan="1" colspan="1">100% (NA)</td><td valign="top" align="left" rowspan="1" colspan="1">Assumed</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Probability of hospitalization</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> After NFOD</td><td valign="top" align="left" rowspan="1" colspan="1">0.9700</td><td valign="top" align="left" rowspan="1" colspan="1">Unpublished data</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> For IE</td><td valign="top" align="left" rowspan="1" colspan="1">0.1500 (0.1330-0.1670)</td><td valign="top" align="left" rowspan="1" colspan="1">N&#8217;Guyen Y et al,<sup><xref rid="zoi230256r23" ref-type="bibr">23</xref></sup> 2017</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> For SSTI</td><td valign="top" align="left" rowspan="1" colspan="1">0.0019 (0.0008-0.0040)</td><td valign="top" align="left" rowspan="1" colspan="1">Hope VD et al,<sup><xref rid="zoi230256r22" ref-type="bibr">22</xref></sup> 2015</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Previous overdose multiplier for risk of subsequent overdose by number of NFODs</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 1</td><td valign="top" align="left" rowspan="1" colspan="1">1.15 (0.72-1.82)</td><td rowspan="4" valign="top" align="left" colspan="1">Caudarella A et al,<sup><xref rid="zoi230256r49" ref-type="bibr">49</xref></sup> 2016</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2-3</td><td valign="top" align="left" rowspan="1" colspan="1">1.81 (1.19-2.27)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 4-7</td><td valign="top" align="left" rowspan="1" colspan="1">2.12 (1.11-4.04)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &#8805;8</td><td valign="top" align="left" rowspan="1" colspan="1">5.24 (1.56-17.01)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Previous infection multiplier for risk of subsequent infection</td><td valign="top" align="left" rowspan="1" colspan="1">2.00 (1.50-5.10)</td><td valign="top" align="left" rowspan="1" colspan="1">Alagna L et al,<sup><xref rid="zoi230256r50" ref-type="bibr">50</xref></sup> 2014</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Inpatient</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Duration of hospitalization for SSTI, mean, wk</td><td valign="top" align="left" rowspan="1" colspan="1">2 (1-4)</td><td valign="top" align="left" rowspan="1" colspan="1">Miller AC and Polgreen PM,<sup><xref rid="zoi230256r51" ref-type="bibr">51</xref></sup> 2019</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Duration of hospitalization for IE, mean (range), wk</td><td valign="top" align="left" rowspan="1" colspan="1">6 (4-8)</td><td valign="top" align="left" rowspan="1" colspan="1">Miller AC and Polgreen PM,<sup><xref rid="zoi230256r51" ref-type="bibr">51</xref></sup> 2019</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Probability of PDD</td><td valign="top" align="left" rowspan="1" colspan="1">0.0300 (0.0125-0.0600)</td><td valign="top" align="left" rowspan="1" colspan="1">Meisner JA et al,<sup><xref rid="zoi230256r52" ref-type="bibr">52</xref></sup> 2020; Kimmel SD et al,<sup><xref rid="zoi230256r53" ref-type="bibr">53</xref></sup> 2021</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Outpatient addiction care linkages</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Linkage to outpatient addiction care after hospitalization if taking MOUD</td><td valign="top" align="left" rowspan="1" colspan="1">0.99 (0.50-0.99)</td><td valign="top" align="left" rowspan="1" colspan="1">Expert opinion</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Linkage to outpatient addiction care</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Status quo</td><td valign="top" align="left" rowspan="1" colspan="1">0.00357 (0.00146-0.01236)</td><td valign="top" align="left" rowspan="1" colspan="1">Hall N et al,<sup><xref rid="zoi230256r54" ref-type="bibr">54</xref></sup> 2021; Lewer et al,<sup><xref rid="zoi230256r55" ref-type="bibr">55</xref></sup> 2020</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> BUP</td><td valign="top" align="left" rowspan="1" colspan="1">0.01700 (0.00850-0.03400)</td><td valign="top" align="left" rowspan="1" colspan="1">Miller AC and Polgreen PM,<sup><xref rid="zoi230256r51" ref-type="bibr">51</xref></sup> 2019; Lewer et al,<sup><xref rid="zoi230256r55" ref-type="bibr">55</xref></sup> 2020</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> BUP plus HR</td><td valign="top" align="left" rowspan="1" colspan="1">0.01700 (0.00850-0.03400)</td><td valign="top" align="left" rowspan="1" colspan="1">Miller AC and Polgreen PM,<sup><xref rid="zoi230256r51" ref-type="bibr">51</xref></sup> 2019; Lewer et al,<sup><xref rid="zoi230256r55" ref-type="bibr">55</xref></sup> 2020</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Outpatient MOUD treatment initiation</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Outpatient addiction care</td><td valign="top" align="left" rowspan="1" colspan="1">0.30 (0.15-0.60)</td><td valign="top" align="left" rowspan="1" colspan="1">Simon CB et al,<sup><xref rid="zoi230256r27" ref-type="bibr">27</xref></sup> 2017</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Outpatient unlinking</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Spontaneous unlinkage from outpatient addiction care with MOUD</td><td valign="top" align="left" rowspan="1" colspan="1">0.037104 (0.018552-0.074208)</td><td valign="top" align="left" rowspan="1" colspan="1">Sohler NL et al,<sup><xref rid="zoi230256r56" ref-type="bibr">56</xref></sup> 2010</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Spontaneous unlinkage from outpatient addiction without MOUD</td><td valign="top" align="left" rowspan="1" colspan="1">0.123952 (0.061976-0.247942)</td><td valign="top" align="left" rowspan="1" colspan="1">Sohler NL et al,<sup><xref rid="zoi230256r56" ref-type="bibr">56</xref></sup> 2010</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Mortality</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Background mortality without overdoses</td><td valign="top" align="left" rowspan="1" colspan="1">Varies by age and sex (0.0008-0.0011)</td><td valign="top" align="left" rowspan="1" colspan="1">Arias E,<sup><xref rid="zoi230256r57" ref-type="bibr">57</xref></sup> 2012; Chang KC et al,<sup><xref rid="zoi230256r58" ref-type="bibr">58</xref></sup> 2017</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Probability of death, untreated</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> IE</td><td valign="top" align="left" rowspan="1" colspan="1">0.1623 (0.0848-0.5358)</td><td valign="top" align="left" rowspan="1" colspan="1">Verhagen DW et al,<sup><xref rid="zoi230256r59" ref-type="bibr">59</xref></sup> 2006; Veldhuizen S and Callaghan RC,<sup><xref rid="zoi230256r60" ref-type="bibr">60</xref></sup> 2014</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> SSTI</td><td valign="top" align="left" rowspan="1" colspan="1">0.0023 (0.0012-0.0028)</td><td valign="top" align="left" rowspan="1" colspan="1">Veldhuizen S and Callaghan RC,<sup><xref rid="zoi230256r60" ref-type="bibr">60</xref></sup> 2014</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Probability of death, inpatient</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> With IE</td><td valign="top" align="left" rowspan="1" colspan="1">0.0100 (0.0018-0.0161)</td><td valign="top" align="left" rowspan="1" colspan="1">Veldhuizen S and Callaghan RC,<sup><xref rid="zoi230256r60" ref-type="bibr">60</xref></sup> 2014; Rodger L et a,<sup><xref rid="zoi230256r61" ref-type="bibr">61</xref></sup> 2018; Cresti A et al,<sup><xref rid="zoi230256r62" ref-type="bibr">62</xref></sup> 2017; Hill EE et al,<sup><xref rid="zoi230256r63" ref-type="bibr">63</xref></sup> 2007; Ternhag A, et al<sup><xref rid="zoi230256r64" ref-type="bibr">64</xref></sup> 2013</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> With SSTI</td><td valign="top" align="left" rowspan="1" colspan="1">0.0006 (0.0004-0.0012)</td><td valign="top" align="left" rowspan="1" colspan="1">Veldhuizen S and Callaghan RC,<sup><xref rid="zoi230256r60" ref-type="bibr">60</xref></sup> 2014</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> With overdose</td><td valign="top" align="left" rowspan="1" colspan="1">0.0190 (0.0130-0.0270)</td><td valign="top" align="left" rowspan="1" colspan="1">Jiang Y et al,<sup><xref rid="zoi230256r65" ref-type="bibr">65</xref></sup> 2017</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Costs, $</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Background </td><td valign="top" align="left" rowspan="1" colspan="1">Varies by age and sex</td><td valign="top" align="left" rowspan="1" colspan="1">AHRQ<sup><xref rid="zoi230256r66" ref-type="bibr">66</xref></sup></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Fatal overdose</td><td valign="top" align="left" rowspan="1" colspan="1">460.59 (230.30-690.00)</td><td valign="top" align="left" rowspan="1" colspan="1">Behrends CN et al,<sup><xref rid="zoi230256r67" ref-type="bibr">67</xref></sup> 2019</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> NFOD, not hospitalized</td><td valign="top" align="left" rowspan="1" colspan="1">1197 (599-1798)</td><td valign="top" align="left" rowspan="1" colspan="1">Behrends CN et al,<sup><xref rid="zoi230256r67" ref-type="bibr">67</xref></sup> 2019</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hospitalization for IE</td><td valign="top" align="left" rowspan="1" colspan="1">23&#8201;091 (8736-34&#8201;410)</td><td valign="top" align="left" rowspan="1" colspan="1">Miller AC and Polgreen PM,<sup><xref rid="zoi230256r51" ref-type="bibr">51</xref></sup> 2019</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hospitalization for SSTI</td><td valign="top" align="left" rowspan="1" colspan="1">19&#8201;001 (9124-26&#8201;378)</td><td valign="top" align="left" rowspan="1" colspan="1">Miller AC and Polgreen PM,<sup><xref rid="zoi230256r51" ref-type="bibr">51</xref></sup> 2019</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hospitalization for overdose</td><td valign="top" align="left" rowspan="1" colspan="1">15&#8201;194 (12&#8201;744-15&#8201;646)</td><td valign="top" align="left" rowspan="1" colspan="1">Behrends CN et al,<sup><xref rid="zoi230256r67" ref-type="bibr">67</xref></sup> 2019</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Inpatient MOUD </td><td valign="top" align="left" rowspan="1" colspan="1">43.63 (21.82-87.26)</td><td valign="top" align="left" rowspan="1" colspan="1">US Department of Veterans Affairs<sup><xref rid="zoi230256r68" ref-type="bibr">68</xref></sup></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Outpatient addiction visit with MOUD</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Status quo</td><td valign="top" align="left" rowspan="1" colspan="1">126.89 (63.44-253.78)</td><td valign="top" align="left" rowspan="1" colspan="1">CMS<sup><xref rid="zoi230256r69" ref-type="bibr">69</xref></sup> and expert opinion<xref rid="zoi230256t1n2" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> BUP</td><td valign="top" align="left" rowspan="1" colspan="1">64.64 (32.32-129.28)</td><td valign="top" align="left" rowspan="1" colspan="1">CMS<sup><xref rid="zoi230256r69" ref-type="bibr">69</xref></sup> and expert opinion<xref rid="zoi230256t1n2" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> BUP plus HR</td><td valign="top" align="left" rowspan="1" colspan="1">68.58 (34.29-137.16)</td><td valign="top" align="left" rowspan="1" colspan="1">CMS<sup><xref rid="zoi230256r69" ref-type="bibr">69</xref></sup> and expert opinion<xref rid="zoi230256t1n2" ref-type="table-fn"><sup>b</sup></xref></td></tr></tbody></table><table-wrap-foot><p>Abbreviations: AHRQ, Agency for Healthcare Research and Quality; BUP, onsite buprenorphine prescribing; BUP plus HR, onsite buprenorphine plus harm reduction; CDC, Centers for Disease Control and Prevention; CMS, Centers for Medicare &amp; Medicaid Services; IE, infective endocarditis; MDPH, Massachusetts Department of Public Health; MOUD, medication for opioid use disorder; NA, not applicable; NFOD, nonfatal overdose; PDD, patient-directed discharge; SSTI, severe skin and soft tissue infection.</p><fn id="zoi230256t1n1"><label>
<sup>a</sup>
</label><p>The the Reducing Infections Related to Drug Use Cost-Effectiveness (REDUCE) model runs on a weekly time cycle; therefore, all probabilities in this table are weekly probabilities. Calibrated inputs have been adjusted to meet the 5 calibration points. See eMethods in <xref rid="note-ZOI230256-1-s" ref-type="supplementary-material">Supplement 1</xref> for a more detailed explanation of the calibration targets.</p></fn><fn id="zoi230256t1n2"><label>
<sup>b</sup>
</label><p>Consensus obtained among the study authors.</p></fn></table-wrap-foot></table-wrap></sec><sec id="H3-7-ZOI230256"><title>Sequelae and Hospitalization</title><p>We estimated the rates of fatal and nonfatal overdose from state-level data.<sup><xref rid="zoi230256r46" ref-type="bibr">46</xref>,<xref rid="zoi230256r47" ref-type="bibr">47</xref>,<xref rid="zoi230256r48" ref-type="bibr">48</xref></sup> We used published literature to estimate the rates of injection-related infections and the proportion of infections that are IE and severe SSTIs.<sup><xref rid="zoi230256r51" ref-type="bibr">51</xref>,<xref rid="zoi230256r71" ref-type="bibr">71</xref>,<xref rid="zoi230256r72" ref-type="bibr">72</xref>,<xref rid="zoi230256r73" ref-type="bibr">73</xref></sup></p></sec><sec id="H3-8-ZOI230256"><title>Outpatient Services</title><p>We used published data to estimate linkage to a PCP, which did not vary by strategy.<sup><xref rid="zoi230256r74" ref-type="bibr">74</xref></sup> For the status quo strategy, we assumed that all patients with OUD would be referred to an offsite addiction specialist for buprenorphine. Each referred individual had a 21% weekly probability of presenting for care,<sup><xref rid="zoi230256r54" ref-type="bibr">54</xref></sup> and those who presented to addiction care had a 30% probability of accepting buprenorphine.<sup><xref rid="zoi230256r27" ref-type="bibr">27</xref></sup> For the BUP and BUP plus HR strategies, we assumed 100% of PCPs would offer buprenorphine at their visits, but patients had a 30% probability of accepting it. We estimated that individuals treated with buprenorphine would be 4 times less likely than those not receiving buprenorphine to unlink from care.<sup><xref rid="zoi230256r75" ref-type="bibr">75</xref></sup> Treatment retention did not differ among the strategies.</p></sec><sec id="H3-9-ZOI230256"><title>Mortality</title><p>We used overdose-removed US age- and sex-adjusted mortality from the National Vital Statistics System<sup><xref rid="zoi230256r57" ref-type="bibr">57</xref></sup> to derive the competing causes of death parameter. Aside from sequelae, persons who inject opioids could encounter additional drug-related mortality risk (eg, other infections and violence).<sup><xref rid="zoi230256r76" ref-type="bibr">76</xref></sup> We accounted for additional opioid-related harms not captured by fatal OD or sequelae by multiplying the resulting mortality rates by 1.2.<sup><xref rid="zoi230256r58" ref-type="bibr">58</xref></sup></p></sec><sec id="H3-10-ZOI230256"><title>Modified Health Care Sector Costs</title><p>We derived estimated health insurance costs from the 2021 Laboratory and Physician Fee Schedules from the Centers for Medicare &amp; Medicaid Services<sup><xref rid="zoi230256r69" ref-type="bibr">69</xref></sup> and the Medical Expenditure Panel Survey.<sup><xref rid="zoi230256r77" ref-type="bibr">77</xref></sup> We did not include out-of-pocket costs, hence the labeling as modified health care sector costs. For the 5-year budgetary impact analysis, we estimated costs to PCPs in their personal practice and assumed the costs of a one-time buprenorphine training, the opportunity cost of attending the training, a 1-month reduction in daily patient visits while the practitioner became familiar with buprenorphine prescribing, and direct purchasing costs for harm reduction supplies and naloxone for 30 patients for 5 years.</p></sec><sec id="H3-11-ZOI230256"><title>Sensitivity Analyses</title><p>We performed deterministic sensitivity analyses (DSAs) to determine the effect of varying model parameters and critical model assumptions. Because there is uncertainty regarding the empirical data used, we performed probabilistic sensitivity analyses (PSAs) to generate quantitative estimates of uncertainty in selected simulated outcomes. For each PSA, we performed 1000 simulations on 1000 people to get a cohort of 1 million persons to ensure a comprehensive range for the parameters that had more uncertainty because of lack of data in the existing literature. We generated a 95% credible interval (Crl) using PSAs for pertinent outcomes. From these PSAs, we also calculated the net monetary benefit of BUP plus HR compared with BUP assuming a willingness-to-pay threshold of $100&#8201;000 per LY.</p></sec></sec></sec><sec id="H1-3-ZOI230256"><title>Results</title><p>Using a microsimulation model of 2&#8201;250&#8201;000 million people in the US who inject opioids (mean [SD] age, 44 [18-99] years; 69% male and 31% female), we found health and cost outcome differences in the 3 modeled strategies. Status quo resulted in 1162 overdose deaths per 10&#8201;000 (95% Crl, 1144-2303) people, whereas both BUP and BUP plus HR resulted in approximately 160 fewer deaths per 10&#8201;000 people (95% CrI for BUP, 802-1718; 95% CrI for BUP plus HR, 692-1810). In the status quo strategy, mortality rates were 5.76% for SSTIs and 38.94% for IE, both of which were greater than in the BUP (2.10% for SSTIs and 36.34% for IE) and BUP plus HR (2.11% for SSTIs and 36.46% for IE) strategies (<xref rid="zoi230256t2" ref-type="table">Table 2</xref>). Compared with the status quo strategy, life expectancy was extended in BUP by 2.65 years and BUP plus HR by 2.71 years (<xref rid="zoi230256t2" ref-type="table">Table 2</xref>). Integrating buprenorphine alone extended discounted life expectancy by 0.16 years and buprenorphine combined with harm reduction kits extended discounted life expectancy by 0.17 years. Status quo resulted in 10&#8201;957 hospitalizations per 10&#8201;000 individuals throughout the lifetime (95% Crl, 14&#8201;270-28 839) (<xref rid="zoi230256t3" ref-type="table">Table 3</xref>). Because BUP and BUP plus HR extended life, they created more person-time exposed to the risks of drug use and, therefore, paradoxically resulted in more hospitalizations: 1454 more in BUP and 1169 more in BUP plus HR. The BUP strategy resulted in 96 more cases of severe SSTIs per 10&#8201;000 individuals than the status quo strategy. In contrast, BUP plus HR resulted in 164 fewer SSTIs per 10&#8201;000 people. Both the BUP and BUP plus HR strategies decreased mortality from all sequelae by approximately 33% compared with the status quo strategy.</p><table-wrap position="float" id="zoi230256t2" orientation="portrait"><label>Table 2. </label><caption><title>Selected Cost and Clinical Outcomes From Base Case Analysis<xref rid="zoi230256t2n1" ref-type="table-fn"><sup>a</sup></xref></title></caption><table frame="hsides" rules="groups"><col width="10.92%" span="1"/><col width="7.32%" span="1"/><col width="7.64%" span="1"/><col width="6.31%" span="1"/><col width="6.71%" span="1"/><col width="6.71%" span="1"/><col width="10.01%" span="1"/><col width="11.18%" span="1"/><col width="12.96%" span="1"/><col width="10.55%" span="1"/><col width="9.69%" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Scenario</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Deaths, No.</th><th colspan="3" valign="top" align="left" scope="colgroup" rowspan="1">Deaths, %</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Life expectancy, y</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1"> Undiscounted lifetime medical costs per person, $</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1"/><th rowspan="2" valign="top" align="left" scope="col" colspan="1">ICER<sup>b</sup></th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Total</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Averted</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Overdose</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">SSTI</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">IE</th><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Discounted cost per person (95% CrI), $</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Discounted LYs (95% CrI)</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Status quo</td><td valign="top" align="left" rowspan="1" colspan="1">772&#8201;722</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">11.17</td><td valign="top" align="left" rowspan="1" colspan="1">5.76</td><td valign="top" align="left" rowspan="1" colspan="1">38.94</td><td valign="top" align="left" rowspan="1" colspan="1">70.72</td><td valign="top" align="left" rowspan="1" colspan="1">773&#8201;000</td><td valign="top" align="left" rowspan="1" colspan="1">203&#8201;500 (203&#8201;000-222&#8201;000)</td><td valign="top" align="left" rowspan="1" colspan="1">6.56 (6.33-6.74)</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">BUP</td><td valign="top" align="left" rowspan="1" colspan="1">517&#8201;795</td><td valign="top" align="left" rowspan="1" colspan="1">254&#8201;927</td><td valign="top" align="left" rowspan="1" colspan="1">11.18</td><td valign="top" align="left" rowspan="1" colspan="1">2.10</td><td valign="top" align="left" rowspan="1" colspan="1">36.34</td><td valign="top" align="left" rowspan="1" colspan="1">73.37</td><td valign="top" align="left" rowspan="1" colspan="1">854&#8201;900 </td><td valign="top" align="left" rowspan="1" colspan="1">209&#8201;400 (201&#8201;000-217&#8201;000)</td><td valign="top" align="left" rowspan="1" colspan="1">6.73 (6.37-6.77)</td><td valign="top" align="left" rowspan="1" colspan="1">Dominated<xref rid="zoi230256t2n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">BUP plus HR</td><td valign="top" align="left" rowspan="1" colspan="1">511&#8201;900</td><td valign="top" align="left" rowspan="1" colspan="1">260&#8201;822</td><td valign="top" align="left" rowspan="1" colspan="1">11.18</td><td valign="top" align="left" rowspan="1" colspan="1">2.11</td><td valign="top" align="left" rowspan="1" colspan="1">36.46</td><td valign="top" align="left" rowspan="1" colspan="1">73.43</td><td valign="top" align="left" rowspan="1" colspan="1">852&#8201;000 </td><td valign="top" align="left" rowspan="1" colspan="1">209&#8201;400 (200&#8201;300-212&#8201;000)</td><td valign="top" align="left" rowspan="1" colspan="1">6.73 (6.43-6.76)</td><td valign="top" align="left" rowspan="1" colspan="1">34&#8201;400</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: BUP, onsite buprenorphine prescribing; BUP plus HR, onsite buprenorphine plus harm reduction; CrI, credible interval; ICER, incremental cost-effectiveness ratio; IE, infective endocarditis; LY, life years; NA, not applicable; SSTI, severe skin and soft tissue infection.</p><fn id="zoi230256t2n1"><label>
<sup>a</sup>
</label><p>All costs were rounded to the nearest tenths for representation on this table; however, cost and ICER calculations used values to the hundredth decimal point. As such, the ICER for a given alternative is higher than that of the next, more effective alternative.</p></fn><fn id="zoi230256t2n2"><label>
<sup>b</sup>
</label><p>The overall ICER was calculated as the difference in the average discounted costs for the total US population divided by the difference in the discounted life expectancy for the total US population, all discounted at 3% per year.</p></fn><fn id="zoi230256t2n3"><label>
<sup>c</sup>
</label><p>Costs more and had worse clinical outcomes.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="zoi230256t3" orientation="portrait"><label>Table 3. </label><caption><title>Selected Clinical Outcomes and Health Care Use Costs From Base Case Analysis</title></caption><table frame="hsides" rules="groups"><col width="12.1%" span="1"/><col width="7.61%" span="1"/><col width="7.61%" span="1"/><col width="7.61%" span="1"/><col width="7.44%" span="1"/><col width="6.45%" span="1"/><col width="18.33%" span="1"/><col width="16.57%" span="1"/><col width="16.14%" span="1"/><col width="0.14%" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Scenario</th><th colspan="3" valign="top" align="left" scope="colgroup" rowspan="1">Averted mortality per 10&#8201;000 people, %</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Completed therapy, %</th><th colspan="4" valign="top" align="left" scope="colgroup" rowspan="1">Total costs per per person (95% CrI), $<xref rid="zoi230256t3n1" ref-type="table-fn"><sup>a</sup></xref></th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">OD</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">SSTI</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">IE</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">SSTI</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">IE</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Hospitalizations</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Outpatient</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Health care</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Status quo</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">78.8</td><td valign="top" align="left" rowspan="1" colspan="1">61.0</td><td valign="top" align="left" rowspan="1" colspan="1">67&#8201;192 (64&#8201;344-142&#8201;003)</td><td valign="top" align="left" rowspan="1" colspan="1">43&#8201;372 (45&#8201;537-54&#8201;579)</td><td valign="top" align="left" rowspan="1" colspan="1">100&#8201;564 (109&#8201;881-196&#8201;582)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">BUP</td><td valign="top" align="left" rowspan="1" colspan="1">160.9</td><td valign="top" align="left" rowspan="1" colspan="1">395.5</td><td valign="top" align="left" rowspan="1" colspan="1">576.5</td><td valign="top" align="left" rowspan="1" colspan="1">91.3</td><td valign="top" align="left" rowspan="1" colspan="1">63.7</td><td valign="top" align="left" rowspan="1" colspan="1">65&#8201;440 (50&#8201;832-101&#8201;161)</td><td valign="top" align="left" rowspan="1" colspan="1">104&#8201;649 (89&#8201;055-103&#8201;998)</td><td valign="top" align="left" rowspan="1" colspan="1">170&#8201;089 (139&#8201;887-205&#8201;159)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">BUP plus HR</td><td valign="top" align="left" rowspan="1" colspan="1">159.8</td><td valign="top" align="left" rowspan="1" colspan="1">399.4</td><td valign="top" align="left" rowspan="1" colspan="1">599.4</td><td valign="top" align="left" rowspan="1" colspan="1">91.3</td><td valign="top" align="left" rowspan="1" colspan="1">63.6</td><td valign="top" align="left" rowspan="1" colspan="1">63&#8201;860 (49&#8201;293-100&#8201;293)</td><td valign="top" align="left" rowspan="1" colspan="1">111&#8201;373 (97&#8201;552-113&#8201;826)</td><td valign="top" align="left" rowspan="1" colspan="1">175&#8201;233 (146&#8201;845-214&#8201;119)</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: BUP, onsite buprenorphine prescribing; BUP plus HR, onsite buprenorphine plus harm reduction; CrI, credible interval; IE, infective endocarditis; NA, not applicable; SSTI, severe skin and soft tissue infection.</p><fn id="zoi230256t3n1"><label>
<sup>a</sup>
</label><p>The 95% CrIs were derived from the probabilistic sensitivity analysis. The CrIs were not calculated for certain outcomes because they are not primary outcomes from the model but rather were calculated by combining multiple outcomes.</p></fn></table-wrap-foot></table-wrap><p>In terms of costs, compared with status quo, the mean undiscounted lifetime medical cost per person was greater for the other strategies: $854&#8201;900 for BUP and $852&#8201;000 for BUP plus HR (<xref rid="zoi230256t2" ref-type="table">Table 2</xref>). The combined total health care costs per person during a lifetime increased with each strategy compared with status quo by 69.1% for BUP and 74.3% for BUP plus HR. We also noted that there was a shift in the cost components away from costs of hospitalization for sequelae of drug use (decreasing per persons by $1752 for BUP and $3332 for BUP plus HR) and toward outpatient costs (increasing by $61&#8201;277 per persons for BUP and $68&#8201;001 per 10&#8201;000 persons for BUP plus HR) (<xref rid="zoi230256t3" ref-type="table">Table 3</xref>). Compared with status quo, BUP plus HR had an ICER of $34&#8201;400 per LY and was considered the cost-effective strategy; the BUP strategy was more expensive and less effective than the next strategy (<xref rid="zoi230256t2" ref-type="table">Table 2</xref>).</p><p>We performed 1-way DSAs on parameters that likely affected life expectancy and costs when comparing BUP plus HR to status quo (eTables 1-43 and eFigures 1 and 2 in <xref rid="note-ZOI230256-1-s" ref-type="supplementary-material">Supplement 1</xref>). In the DSA that assumed lower linkage probability to outpatient addiction care in inpatient or background settings, BUP had the greater cost, more LYs gained, and an ICER of $66&#8201;040 when compared with BUP plus HR. The BUP plus HR strategy remained the preferred strategy, with an ICER of $35&#8201;570 per LY gained compared with BUP (eTable 18 in <xref rid="note-ZOI230256-1-s" ref-type="supplementary-material">Supplement 1</xref>). In the DSA assuming lower IE hospitalization rates, BUP was the preferred strategy, with an ICER of $43&#8201;244 when compared with status quo (eTable 26 in <xref rid="note-ZOI230256-1-s" ref-type="supplementary-material">Supplement 1</xref>).</p><p>Finally, our PSA showed that under different assumptions about parameter values, some of our clinical outcomes had wide ranges and overlapping CrIs between status quo and other strategies (eTable 45 in <xref rid="note-ZOI230256-1-s" ref-type="supplementary-material">Supplement 1</xref>). In our PSAs, BUP plus HR was the preferred strategy 76% of the time at a willingness-to-pay threshold of $100&#8201;000 per LY. In the budgetary impact analysis from the PCP perspective, we estimated that the total cost of BUP plus HR during a 5-year period to an individual PCP practice was approximately $13&#8201;000 (<xref rid="zoi230256t4" ref-type="table">Table 4</xref>).<sup><xref rid="zoi230256r78" ref-type="bibr">78</xref>,<xref rid="zoi230256r79" ref-type="bibr">79</xref></sup></p><table-wrap position="float" id="zoi230256t4" orientation="portrait"><label>Table 4. </label><caption><title>Five-Year Budgetary Impact Analysis From PCP Perspective to Offer Onsite BUP Plus HR</title></caption><table frame="hsides" rules="groups"><col width="65.35%" span="1"/><col width="20.44%" span="1"/><col width="14.21%" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Variable</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Estimated cost amount, $</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Source</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Attending 1-time 8-hour buprenorphine waiver training</td><td valign="top" align="left" rowspan="1" colspan="1">149.00</td><td valign="top" align="left" rowspan="1" colspan="1">SAMHSA<sup><xref rid="zoi230256r78" ref-type="bibr">78</xref></sup></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Opportunity cost to attend an 8-hour buprenorphine training</td><td valign="top" align="left" rowspan="1" colspan="1">707.20</td><td valign="top" align="left" rowspan="1" colspan="1">SAMHSA<sup><xref rid="zoi230256r79" ref-type="bibr">79</xref></sup></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">1-Month reduction in volume of daily patient visits to account for providers becoming familiar with buprenorphine prescribing</td><td valign="top" align="left" rowspan="1" colspan="1">5000.00</td><td valign="top" align="left" rowspan="1" colspan="1">Expert opinion<xref rid="zoi230256t4n1" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Direct PCP purchasing of harm reduction supplies and naloxone for a panel of 30 patients</td><td valign="top" align="left" rowspan="1" colspan="1">7092.00</td><td valign="top" align="left" rowspan="1" colspan="1">Expert opinion<xref rid="zoi230256t4n2" ref-type="table-fn"><sup>b</sup></xref></td></tr></tbody></table><table-wrap-foot><p>Abbreviations: BUP plus HR, onsite buprenorphine plus harm reduction; PCP, primary care practitioner; SAMHSA, Substance Abuse and Mental Health Services Administration.</p><fn id="zoi230256t4n1"><label>
<sup>a</sup>
</label><p>Todd Kerensky, MD, South Shore Health, South Weymouth, Massachusetts, written communication, February 28, 2022.</p></fn><fn id="zoi230256t4n2"><label>
<sup>b</sup>
</label><p>S.K., written communication, January 24, 2022.</p></fn></table-wrap-foot></table-wrap></sec><sec id="H1-4-ZOI230256"><title>Discussion</title><p>In this microsimulation modeling study of US people who inject drugs, we estimated the long-term clinical outcomes, costs, and cost-effectiveness of integrating onsite addiction care into primary care. We found that BUP plus HR improved clinical outcomes, averted sequelae, and increased life expectancy compared with status quo and was cost-effective. Our results suggest that integrated addiction care in primary care has the potential to save lives and increase nonemergency health care use, which is consistent with prior literature.<sup><xref rid="zoi230256r80" ref-type="bibr">80</xref>,<xref rid="zoi230256r81" ref-type="bibr">81</xref></sup> Colocated addiction services within primary care is pragmatic and effective and has comparable quality to specialty care.<sup><xref rid="zoi230256r82" ref-type="bibr">82</xref></sup> We found that onsite BUP plus HR provides better outcomes than BUP alone at a lower cost.</p><p>Even though treatment with buprenorphine has lifesaving properties on its own, people who are actively using or injecting drugs may not desire pharmacotherapy because of concerns about precipitated withdrawal, practitioner stigma,<sup><xref rid="zoi230256r10" ref-type="bibr">10</xref></sup> lack of health insurance,<sup><xref rid="zoi230256r83" ref-type="bibr">83</xref></sup> and high copayments.<sup><xref rid="zoi230256r84" ref-type="bibr">84</xref>,<xref rid="zoi230256r85" ref-type="bibr">85</xref></sup> Onsite harm reduction tools are not currently part of the traditional medical model<sup><xref rid="zoi230256r86" ref-type="bibr">86</xref></sup>; however, integrating harm reduction kits into care could provide patients with treatment autonomy and serve as tools for treatment engagement in times of active and/or chaotic use.<sup><xref rid="zoi230256r87" ref-type="bibr">87</xref></sup> Our model for onsite harm reduction kits provided a fixed quantity of safer injection and wound care equipment that may not last 1 week (or even 1 day) for higher-frequency users. That there was still a mortality benefit is notable. Furthermore, although our study modeled impact of harm reduction kits during office PCP visits, kits could be delivered in other ways, including with nurses (during billable visits) or via outreach staff, which could increase patient engagement in health care but may alter our cost and care use estimates. Future work should also evaluate the impact of BUP plus HR for PCPs in rural areas, which may have limited access to community-based harm reduction organizations and sterile equipment.</p><p>Prior studies demonstrated that buprenorphine in outpatient settings is cost-effective.<sup><xref rid="zoi230256r88" ref-type="bibr">88</xref>,<xref rid="zoi230256r89" ref-type="bibr">89</xref></sup> Our findings demonstrate that BUP plus HR is cost-effective from a health care sector perspective, but individual PCPs may shoulder the burden of costs. In our budget impact analysis, we estimated that the 5-year cost to a PCP might reach $13&#8201;000, which includes both direct resource and opportunity costs. These costs could be offset by the savings incurred by the health care system. These costs included those for X-waiver training, which has been eliminated; thus, we expect this to cost less. Put another way, our findings inform ways to reinvest health care dollars as financial incentives for PCPs to adopt this new paradigm. Public health departments could provide grants or harm reduction kit supplies directly to PCPs to offset these costs as they do in some places with syringe service programs and/or increase Medicaid reimbursements for providing addiction care in primary care.<sup><xref rid="zoi230256r90" ref-type="bibr">90</xref></sup></p><p>Although we found that integrating buprenorphine prescribing and harm reduction kits in primary care will decrease patient mortality from overdose, severe SSTIs, and IE, it paradoxically increases the total number of hospitalizations and overall costs. If more individuals stay alive longer, they have more time to engage in health care during their lives. A single-center study alluded to a similar paradoxical cost benefit with a reduction in hospitalization cost but higher cost for buprenorphine prescriptions at 1 year for integrated buprenorphine in primary care.<sup><xref rid="zoi230256r91" ref-type="bibr">91</xref></sup> Because our study models people throughout a lifetime, the BUP plus HR strategy could save lives, prevent injection-related infections, and offload costs from short-term hospitalizations to outpatient settings. Practically, this also means that people who use drugs could have greater opportunities to engage with outpatient PCPs from whom they could receive care for other chronic illnesses<sup><xref rid="zoi230256r92" ref-type="bibr">92</xref></sup> and receive expedited management of injection-related sequelae, leading to higher infection cure rates. Furthermore, the implications of these averted lengthy hospital stays could financially benefit hospital systems, which may have greater capacity to care for individuals with other conditions.</p><sec id="H2-4-ZOI230256"><title>Limitations</title><p>Our study has several limitations. First, we relied on a single published study<sup><xref rid="zoi230256r75" ref-type="bibr">75</xref></sup> to inform parameters on linkage and retention on buprenorphine therapy. Authors with clinical expertise (R.J., S.L.C., L.R.M., S.D.K., and J.A.B.) note, however, that their clinical practices were within the parameter range, lending validity to the input. Second, although important model parameters were informed by studies of the target population, unmeasured confounders may have impacted the results of these studies. Third, given the heterogeneity of how addiction care is provided in the US, we assumed that in the status quo strategy, all patients access addiction specialty care via a referral mechanism and for simplicity&#8217;s sake included buprenorphine as the only MOUD modality. These assumptions could have overestimated the impact in the model. Fourth, for the status quo and BUP strategies, we assumed that individuals have linkage to harm reduction supplies in the community, which did not account for any addiction specialists who may have incorporated harm reduction supplies within their own practice. Despite these limitations, our findings did not qualitatively change in sensitivity analyses when varying assumptions were used. Fifth, it is unclear whether PCPs and/or health care entities will be willing to adopt this intervention, because it may increase workload. The extent to which this intervention is adopted will alter the associated health impact.</p></sec></sec><sec id="H1-5-ZOI230256"><title>Conclusions</title><p>The findings of this decision analytical model suggest that integrating buprenorphine and harm reduction kits in primary care will improve clinical outcomes and modestly increase costs. There is a clinical and cost benefit of adding harm reduction services onsite along with buprenorphine. Providing these lifesaving tools in primary care should be a health care system priority.</p></sec></body><back><ref-list id="REF-ZOI230256"><title>References</title><ref id="zoi230256r1"><label>1</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Ciccarone</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Unick</surname><given-names>GJ</given-names></string-name>, <string-name name-style="western"><surname>Cohen</surname><given-names>JK</given-names></string-name>, <string-name name-style="western"><surname>Mars</surname><given-names>SG</given-names></string-name>, <string-name name-style="western"><surname>Rosenblum</surname><given-names>D</given-names></string-name></person-group>. <article-title>Nationwide increase in hospitalizations for heroin-related soft tissue infections: associations with structural market conditions</article-title>. <source>Drug Alcohol Depend</source>. <year>2016</year>;<volume>163</volume>:<fpage>126</fpage>-<lpage>133</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2016.04.009</pub-id><pub-id pub-id-type="pmid">27155756</pub-id><pub-id pub-id-type="pmcid">PMC4881875</pub-id></mixed-citation></ref><ref id="zoi230256r2"><label>2</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Schranz</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Fleischauer</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Chu</surname><given-names>VH</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>LT</given-names></string-name>, <string-name name-style="western"><surname>Rosen</surname><given-names>DL</given-names></string-name></person-group>. <article-title>Trends in drug use-associated infective endocarditis and heart valve surgery, 2007 to 2017: a study of statewide discharge data</article-title>. <source>Ann Intern Med</source>. <year>2019</year>;<volume>170</volume>(<issue>1</issue>):<fpage>31</fpage>-<lpage>40</lpage>. doi:<pub-id pub-id-type="doi">10.7326/M18-2124</pub-id><pub-id pub-id-type="pmid">30508432</pub-id><pub-id pub-id-type="pmcid">PMC6548681</pub-id></mixed-citation></ref><ref id="zoi230256r3"><label>3</label><mixed-citation publication-type="webpage"><person-group><collab>US Department of Health and Human Resources</collab></person-group>. Projecting the supply and demand for primary care practitioners through 2020. November 2013. Accessed January 20, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://bhw.hrsa.gov/sites/default/files/bureau-health-workforce/data-research/projecting-primary-care.pdf" ext-link-type="uri">https://bhw.hrsa.gov/sites/default/files/bureau-health-workforce/data-research/projecting-primary-care.pdf</ext-link></mixed-citation></ref><ref id="zoi230256r4"><label>4</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>McGinty</surname><given-names>EE</given-names></string-name>, <string-name name-style="western"><surname>Stone</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Kennedy-Hendricks</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bachhuber</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Barry</surname><given-names>CL</given-names></string-name></person-group>. <article-title>Medication for opioid use disorder: a national survey of primary care physicians</article-title>. <source>Ann Intern Med</source>. <year>2020</year>;<volume>173</volume>(<issue>2</issue>):<fpage>160</fpage>-<lpage>162</lpage>. doi:<pub-id pub-id-type="doi">10.7326/M19-3975</pub-id><pub-id pub-id-type="pmid">32311740</pub-id><pub-id pub-id-type="pmcid">PMC8171002</pub-id></mixed-citation></ref><ref id="zoi230256r5"><label>5</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Barry</surname><given-names>DT</given-names></string-name>, <string-name name-style="western"><surname>Irwin</surname><given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>ES</given-names></string-name>, <etal/></person-group>. <article-title>Integrating buprenorphine treatment into office-based practice: a qualitative study</article-title>. <source>J Gen Intern Med</source>. <year>2009</year>;<volume>24</volume>(<issue>2</issue>):<fpage>218</fpage>-<lpage>225</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11606-008-0881-9</pub-id><pub-id pub-id-type="pmid">19089500</pub-id><pub-id pub-id-type="pmcid">PMC2628993</pub-id></mixed-citation></ref><ref id="zoi230256r6"><label>6</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Hutchinson</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Catlin</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Andrilla</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Baldwin</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Rosenblatt</surname><given-names>RA</given-names></string-name></person-group>. <article-title>Barriers to primary care physicians prescribing buprenorphine</article-title>. <source>Ann Fam Med</source>. <year>2014</year>;<volume>12</volume>(<issue>2</issue>):<fpage>128</fpage>-<lpage>133</lpage>. doi:<pub-id pub-id-type="doi">10.1370/afm.1595</pub-id><pub-id pub-id-type="pmid">24615308</pub-id><pub-id pub-id-type="pmcid">PMC3948759</pub-id></mixed-citation></ref><ref id="zoi230256r7"><label>7</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Olfson</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Schoenbaum</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>King</surname><given-names>M</given-names></string-name></person-group>. <article-title>Buprenorphine treatment by primary care providers, psychiatrists, addiction specialists, and others</article-title>. <source>Health Aff (Millwood)</source>. <year>2020</year>;<volume>39</volume>(<issue>6</issue>):<fpage>984</fpage>-<lpage>992</lpage>. doi:<pub-id pub-id-type="doi">10.1377/hlthaff.2019.01622</pub-id><pub-id pub-id-type="pmid">32479224</pub-id><pub-id pub-id-type="pmcid">PMC9097821</pub-id></mixed-citation></ref><ref id="zoi230256r8"><label>8</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>McBain</surname><given-names>RK</given-names></string-name>, <string-name name-style="western"><surname>Dick</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sorbero</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Stein</surname><given-names>BD</given-names></string-name></person-group>. <article-title>Growth and distribution of buprenorphine-waivered providers in the United States, 2007-2017</article-title>. <source>Ann Intern Med</source>. <year>2020</year>;<volume>172</volume>(<issue>7</issue>):<fpage>504</fpage>-<lpage>506</lpage>. doi:<pub-id pub-id-type="doi">10.7326/M19-2403</pub-id><pub-id pub-id-type="pmid">31905379</pub-id><pub-id pub-id-type="pmcid">PMC7217729</pub-id></mixed-citation></ref><ref id="zoi230256r9"><label>9</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Walley</surname><given-names>AY</given-names></string-name>, <string-name name-style="western"><surname>Alperen</surname><given-names>JK</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>DM</given-names></string-name>, <etal/></person-group>. <article-title>Office-based management of opioid dependence with buprenorphine: clinical practices and barriers</article-title>. <source>J Gen Intern Med</source>. <year>2008</year>;<volume>23</volume>(<issue>9</issue>):<fpage>1393</fpage>-<lpage>1398</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11606-008-0686-x</pub-id><pub-id pub-id-type="pmid">18592319</pub-id><pub-id pub-id-type="pmcid">PMC2518016</pub-id></mixed-citation></ref><ref id="zoi230256r10"><label>10</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Louie</surname><given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Assefa</surname><given-names>MT</given-names></string-name>, <string-name name-style="western"><surname>McGovern</surname><given-names>MP</given-names></string-name></person-group>. <article-title>Attitudes of primary care physicians toward prescribing buprenorphine: a narrative review</article-title>. <source>BMC Fam Pract</source>. <year>2019</year>;<volume>20</volume>(<issue>1</issue>):<fpage>157</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12875-019-1047-z</pub-id><pub-id pub-id-type="pmid">31729957</pub-id><pub-id pub-id-type="pmcid">PMC6857230</pub-id></mixed-citation></ref><ref id="zoi230256r11"><label>11</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Weimer</surname><given-names>MB</given-names></string-name>, <string-name name-style="western"><surname>Wakeman</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Saitz</surname><given-names>R</given-names></string-name></person-group>. <article-title>Removing one barrier to opioid use disorder treatment: is it enough?</article-title><source>JAMA</source>. <year>2021</year>;<volume>325</volume>(<issue>12</issue>):<fpage>1147</fpage>-<lpage>1148</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2021.0958</pub-id><pub-id pub-id-type="pmid">33630020</pub-id></mixed-citation></ref><ref id="zoi230256r12"><label>12</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Edelman</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Oldfield</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Tetrault</surname><given-names>JM</given-names></string-name></person-group>. <article-title>Office-based addiction treatment in primary care: approaches that work</article-title>. <source>Med Clin North Am</source>. <year>2018</year>;<volume>102</volume>(<issue>4</issue>):<fpage>635</fpage>-<lpage>652</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.mcna.2018.02.007</pub-id><pub-id pub-id-type="pmid">29933820</pub-id></mixed-citation></ref><ref id="zoi230256r13"><label>13</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Lagisetty</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Klasa</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Bush</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Heisler</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Chopra</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Bohnert</surname><given-names>A</given-names></string-name></person-group>. <article-title>Primary care models for treating opioid use disorders: what actually works? a systematic review</article-title>. <source>PLoS One</source>. <year>2017</year>;<volume>12</volume>(<issue>10</issue>):<elocation-id>e0186315</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0186315</pub-id><pub-id pub-id-type="pmid">29040331</pub-id><pub-id pub-id-type="pmcid">PMC5645096</pub-id></mixed-citation></ref><ref id="zoi230256r14"><label>14</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Vearrier</surname><given-names>L</given-names></string-name></person-group>. <article-title>The value of harm reduction for injection drug use: a clinical and public health ethics analysis</article-title>. <source>Dis Mon</source>. <year>2019</year>;<volume>65</volume>(<issue>5</issue>):<fpage>119</fpage>-<lpage>141</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.disamonth.2018.12.002</pub-id><pub-id pub-id-type="pmid">30600096</pub-id></mixed-citation></ref><ref id="zoi230256r15"><label>15</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Perera</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Stephan</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Appa</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Meeting people where they are: implementing hospital-based substance use harm reduction</article-title>. <source>Harm Reduct J</source>. <year>2022</year>;<volume>19</volume>(<issue>1</issue>):<fpage>14</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12954-022-00594-9</pub-id><pub-id pub-id-type="pmid">35139877</pub-id><pub-id pub-id-type="pmcid">PMC8826677</pub-id></mixed-citation></ref><ref id="zoi230256r16"><label>16</label><mixed-citation publication-type="webpage"><person-group><collab>Substance Abuse and Mental Health Services Administration</collab></person-group>. Harm Reduction. Accessed February 1, 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.samhsa.gov/find-help/harm-reduction" ext-link-type="uri">https://www.samhsa.gov/find-help/harm-reduction</ext-link></mixed-citation></ref><ref id="zoi230256r17"><label>17</label><mixed-citation publication-type="webpage"><person-group><collab>ABIM Foundation</collab></person-group>. Surveys of Trust in the U.S. Health Care System. Accessed August 4, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://buildingtrust.org/wp-content/uploads/2021/05/20210520_NORC_ABIM_Foundation_Trust-in-Healthcare_Part-1.pdf" ext-link-type="uri">https://buildingtrust.org/wp-content/uploads/2021/05/20210520_NORC_ABIM_Foundation_Trust-in-Healthcare_Part-1.pdf</ext-link></mixed-citation></ref><ref id="zoi230256r18"><label>18</label><mixed-citation publication-type="book"><person-group><string-name name-style="western"><surname>Neumann</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Russell</surname><given-names>LB</given-names></string-name>, <string-name name-style="western"><surname>Sanders</surname><given-names>GD</given-names></string-name>, <string-name name-style="western"><surname>Siegel</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Ganiats</surname><given-names>TG</given-names></string-name></person-group>. <source>Cost Effectiveness in Health and Medicine</source>. <edition>2nd ed</edition>. <publisher-name>Oxford University Press</publisher-name>; <year>2017</year>.</mixed-citation></ref><ref id="zoi230256r19"><label>19</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Barocas</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Eftekhari Yazdi</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Savinkina</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Long-term infective endocarditis mortality associated with injection opioid use in the United States: a modeling study</article-title>. <source>Clin Infect Dis</source>. <year>2021</year>;<volume>73</volume>(<issue>11</issue>):<fpage>e3661</fpage>-<lpage>e3669</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/ciaa1346</pub-id><pub-id pub-id-type="pmid">32901815</pub-id><pub-id pub-id-type="pmcid">PMC8662770</pub-id></mixed-citation></ref><ref id="zoi230256r20"><label>20</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Barocas</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Savinkina</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Adams</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Clinical impact, costs, and cost-effectiveness of hospital-based strategies for addressing the US opioid epidemic: a modelling study</article-title>. <source>Lancet Public Health</source>. <year>2022</year>;<volume>7</volume>(<issue>1</issue>):<fpage>e56</fpage>-<lpage>e64</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2468-2667(21)00248-6</pub-id><pub-id pub-id-type="pmid">34861189</pub-id><pub-id pub-id-type="pmcid">PMC8756295</pub-id></mixed-citation></ref><ref id="zoi230256r21"><label>21</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Adams</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Savinkina</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hudspeth</surname><given-names>JC</given-names></string-name>, <etal/></person-group>. <article-title>Simulated cost-effectiveness and long-term clinical outcomes of addiction care and antibiotic therapy strategies for patients with injection drug use&#8211;associated infective endocarditis</article-title>. <source>JAMA Netw Open</source>. <year>2022</year>;<volume>5</volume>(<issue>2</issue>):<elocation-id>e220541</elocation-id>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.0541</pub-id><pub-id pub-id-type="pmid">35226078</pub-id><pub-id pub-id-type="pmcid">PMC8886538</pub-id></mixed-citation></ref><ref id="zoi230256r22"><label>22</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Hope</surname><given-names>VD</given-names></string-name>, <string-name name-style="western"><surname>Ncube</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Parry</surname><given-names>JV</given-names></string-name>, <string-name name-style="western"><surname>Hickman</surname><given-names>M</given-names></string-name></person-group>. <article-title>Healthcare seeking and hospital admissions by people who inject drugs in response to symptoms of injection site infections or injuries in three urban areas of England</article-title>. <source>Epidemiol Infect</source>. <year>2015</year>;<volume>143</volume>(<issue>1</issue>):<fpage>120</fpage>-<lpage>131</lpage>. doi:<pub-id pub-id-type="doi">10.1017/S0950268814000284</pub-id><pub-id pub-id-type="pmid">24568684</pub-id><pub-id pub-id-type="pmcid">PMC9206814</pub-id></mixed-citation></ref><ref id="zoi230256r23"><label>23</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>N&#8217;Guyen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Duval</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Revest</surname><given-names>M</given-names></string-name>, <etal/>; <collab>AEPEI study group</collab></person-group>. <article-title>Time interval between infective endocarditis first symptoms and diagnosis: relationship to infective endocarditis characteristics, microorganisms and prognosis</article-title>. <source>Ann Med</source>. <year>2017</year>;<volume>49</volume>(<issue>2</issue>):<fpage>117</fpage>-<lpage>125</lpage>. doi:<pub-id pub-id-type="doi">10.1080/07853890.2016.1235282</pub-id><pub-id pub-id-type="pmid">27607562</pub-id></mixed-citation></ref><ref id="zoi230256r24"><label>24</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Priest</surname><given-names>KC</given-names></string-name>, <string-name name-style="western"><surname>McCarty</surname><given-names>D</given-names></string-name></person-group>. <article-title>Making the business case for an addiction medicine consult service: a qualitative analysis</article-title>. <source>BMC Health Serv Res</source>. <year>2019</year>;<volume>19</volume>(<issue>1</issue>):<fpage>822</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12913-019-4670-4</pub-id><pub-id pub-id-type="pmid">31703741</pub-id><pub-id pub-id-type="pmcid">PMC6842195</pub-id></mixed-citation></ref><ref id="zoi230256r25"><label>25</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Englander</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Davis</surname><given-names>CS</given-names></string-name></person-group>. <article-title>Hospital standards of care for people with substance use disorder</article-title>. <source>N Engl J Med</source>. <year>2022</year>;<volume>387</volume>(<issue>8</issue>):<fpage>672</fpage>-<lpage>675</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMp2204687</pub-id><pub-id pub-id-type="pmid">35984354</pub-id></mixed-citation></ref><ref id="zoi230256r26"><label>26</label><mixed-citation publication-type="webpage"><person-group><collab>Substance Abuse and Mental Health Services Administration</collab></person-group>. <italic toggle="yes">Medications for Opioid Use Disorder.</italic> Treatment Improvement Protocol (TIP) Series 63. US Dept of Health &amp; Human Services; <year>2018</year>. HHS publication (SMA) 18-5063FULLDOC. Accessed March 7, 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://store.samhsa.gov/sites/default/files/pep21-02-01-002.pdf" ext-link-type="uri">https://store.samhsa.gov/sites/default/files/pep21-02-01-002.pdf</ext-link></mixed-citation></ref><ref id="zoi230256r27"><label>27</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Simon</surname><given-names>CB</given-names></string-name>, <string-name name-style="western"><surname>Tsui</surname><given-names>JI</given-names></string-name>, <string-name name-style="western"><surname>Merrill</surname><given-names>JO</given-names></string-name>, <string-name name-style="western"><surname>Adwell</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Tamru</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Klein</surname><given-names>JW</given-names></string-name></person-group>. <article-title>Linking patients with buprenorphine treatment in primary care: predictors of engagement</article-title>. <source>Drug Alcohol Depend</source>. <year>2017</year>;<volume>181</volume>:<fpage>58</fpage>-<lpage>62</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2017.09.017</pub-id><pub-id pub-id-type="pmid">29035705</pub-id></mixed-citation></ref><ref id="zoi230256r28"><label>28</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Lansky</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Finlayson</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Johnson</surname><given-names>C</given-names></string-name>, <etal/></person-group>. <article-title>Estimating the number of persons who inject drugs in the United States by meta-analysis to calculate national rates of HIV and hepatitis C virus infections</article-title>. <source>PLoS One</source>. <year>2014</year>;<volume>9</volume>(<issue>5</issue>):<elocation-id>e97596</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0097596</pub-id><pub-id pub-id-type="pmid">24840662</pub-id><pub-id pub-id-type="pmcid">PMC4026524</pub-id></mixed-citation></ref><ref id="zoi230256r29"><label>29</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Martins</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Sarvet</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Santaella-Tenorio</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Saha</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Grant</surname><given-names>BF</given-names></string-name>, <string-name name-style="western"><surname>Hasin</surname><given-names>DS</given-names></string-name></person-group>. <article-title>Changes in US lifetime heroin use and heroin use disorder: prevalence from the 2001-2002 to 2012-2013 National Epidemiologic Survey on Alcohol and Related Conditions</article-title>. <source>JAMA Psychiatry</source>. <year>2017</year>;<volume>74</volume>(<issue>5</issue>):<fpage>445</fpage>-<lpage>455</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamapsychiatry.2017.0113</pub-id><pub-id pub-id-type="pmid">28355458</pub-id><pub-id pub-id-type="pmcid">PMC5470460</pub-id></mixed-citation></ref><ref id="zoi230256r30"><label>30</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Degenhardt</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Peacock</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Colledge</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review</article-title>. <source>Lancet Glob Health</source>. <year>2017</year>;<volume>5</volume>(<issue>12</issue>):<fpage>e1192</fpage>-<lpage>e1207</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2214-109X(17)30375-3</pub-id><pub-id pub-id-type="pmid">29074409</pub-id><pub-id pub-id-type="pmcid">PMC5683738</pub-id></mixed-citation></ref><ref id="zoi230256r31"><label>31</label><mixed-citation publication-type="webpage"><person-group><collab>Centers for Disease Control and Prevention</collab></person-group>. <article-title>HIV infection, risk, prevention, and testing behaviors among persons who inject drugs&#8212;National HIV Behavioral Surveillance: injection drug use, 20 U.S. cities</article-title>, <year>2015</year>. HIV Surveillance Special Report 18. Revised edition. Published May 2018. Accessed January 1, 2020. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-special-report-number-24.pdf" ext-link-type="uri">https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-special-report-number-24.pdf</ext-link></mixed-citation></ref><ref id="zoi230256r32"><label>32</label><mixed-citation publication-type="webpage"><person-group><collab>US Census Bureau</collab></person-group>. Data from: Table DP05 - ACS Demographic and Housing Estimates. <year>2016</year>. Accessed March 7, 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.census.gov/acs/www/data/data-tables-and-tools/data-profiles/2016" ext-link-type="uri">https://www.census.gov/acs/www/data/data-tables-and-tools/data-profiles/2016</ext-link></mixed-citation></ref><ref id="zoi230256r33"><label>33</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Tan</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Makela</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Heller</surname><given-names>D</given-names></string-name>, <etal/></person-group>. <article-title>A Bayesian evidence synthesis approach to estimate disease prevalence in hard-to-reach populations: hepatitis C in New York City</article-title>. <source>Epidemics</source>. <year>2018</year>;<volume>23</volume>:<fpage>96</fpage>-<lpage>109</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.epidem.2018.01.002</pub-id><pub-id pub-id-type="pmid">29666018</pub-id></mixed-citation></ref><ref id="zoi230256r34"><label>34</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Buresh</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Genberg</surname><given-names>BL</given-names></string-name>, <string-name name-style="western"><surname>Astemborski</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kirk</surname><given-names>GD</given-names></string-name>, <string-name name-style="western"><surname>Mehta</surname><given-names>SH</given-names></string-name></person-group>. <article-title>Recent fentanyl use among people who inject drugs: results from a rapid assessment in Baltimore, Maryland</article-title>. <source>Int J Drug Policy</source>. <year>2019</year>;<volume>74</volume>:<fpage>41</fpage>-<lpage>46</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drugpo.2019.08.006</pub-id><pub-id pub-id-type="pmid">31522072</pub-id><pub-id pub-id-type="pmcid">PMC6893143</pub-id></mixed-citation></ref><ref id="zoi230256r35"><label>35</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Smith</surname><given-names>BD</given-names></string-name>, <string-name name-style="western"><surname>Jewett</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Burt</surname><given-names>RD</given-names></string-name>, <string-name name-style="western"><surname>Zibbell</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Yartel</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>DiNenno</surname><given-names>E</given-names></string-name></person-group>. <article-title>&#8220;To share or not to share?&#8221; serosorting by hepatitis C status in the sharing of drug injection equipment among NHBS-IDU2 participants</article-title>. <source>J Infect Dis</source>. <year>2013</year>;<volume>208</volume>(<issue>12</issue>):<fpage>1934</fpage>-<lpage>1942</lpage>. doi:<pub-id pub-id-type="doi">10.1093/infdis/jit520</pub-id><pub-id pub-id-type="pmid">24136794</pub-id><pub-id pub-id-type="pmcid">PMC5759767</pub-id></mixed-citation></ref><ref id="zoi230256r36"><label>36</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Abara</surname><given-names>WE</given-names></string-name>, <string-name name-style="western"><surname>Trujillo</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Broz</surname><given-names>D</given-names></string-name>, <etal/></person-group>. <article-title>Age-related differences in past or present hepatitis C virus infection among people who inject drugs: national human immunodeficiency virus behavioral surveillance, 8 US cities, 2015</article-title>. <source>J Infect Dis</source>. <year>2019</year>;<volume>220</volume>(<issue>3</issue>):<fpage>377</fpage>-<lpage>385</lpage>. doi:<pub-id pub-id-type="doi">10.1093/infdis/jiz142</pub-id><pub-id pub-id-type="pmid">30915477</pub-id><pub-id pub-id-type="pmcid">PMC11111175</pub-id></mixed-citation></ref><ref id="zoi230256r37"><label>37</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Kim</surname><given-names>NJ</given-names></string-name>, <string-name name-style="western"><surname>Jin</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>McFarland</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Raymond</surname><given-names>HF</given-names></string-name></person-group>. <article-title>Trends in sources and sharing of needles among people who inject drugs, San Francisco, 2005-2012</article-title>. <source>Int J Drug Policy</source>. <year>2015</year>;<volume>26</volume>(<issue>12</issue>):<fpage>1238</fpage>-<lpage>1243</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drugpo.2015.08.013</pub-id><pub-id pub-id-type="pmid">26365768</pub-id></mixed-citation></ref><ref id="zoi230256r38"><label>38</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Asher</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Zhong</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Garfein</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Cuevas-Mota</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Teshale</surname><given-names>E</given-names></string-name></person-group>. <article-title>Association of self-reported abscess with high-risk injection-related behaviors among young persons who inject drugs</article-title>. <source>J Assoc Nurses AIDS Care</source>. <year>2019</year>;<volume>30</volume>(<issue>2</issue>):<fpage>142</fpage>-<lpage>150</lpage>. doi:<pub-id pub-id-type="doi">10.1097/JNC.0000000000000016</pub-id><pub-id pub-id-type="pmid">30822287</pub-id><pub-id pub-id-type="pmcid">PMC11474460</pub-id></mixed-citation></ref><ref id="zoi230256r39"><label>39</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Ropelewski</surname><given-names>LR</given-names></string-name>, <string-name name-style="western"><surname>Mancha</surname><given-names>BE</given-names></string-name>, <string-name name-style="western"><surname>Hulbert</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rudolph</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Martins</surname><given-names>SS</given-names></string-name></person-group>. <article-title>Correlates of risky injection practices among past-year injection drug users among the US general population</article-title>. <source>Drug Alcohol Depend</source>. <year>2011</year>;<volume>116</volume>(<issue>1-3</issue>):<fpage>64</fpage>-<lpage>71</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2010.11.025</pub-id><pub-id pub-id-type="pmid">21227602</pub-id><pub-id pub-id-type="pmcid">PMC3090520</pub-id></mixed-citation></ref><ref id="zoi230256r40"><label>40</label><mixed-citation publication-type="webpage"><person-group><collab>Massachusetts Department of Public Health</collab></person-group>. Opioid-related EMS Transports Massachusetts Residents (2013&#8211;2015). Commonwealth of Massachusetts, Dept of Public Health; 2016. Accessed March 7, 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://archives.lib.state.ma.us/handle/2452/396531" ext-link-type="uri">https://archives.lib.state.ma.us/handle/2452/396531</ext-link></mixed-citation></ref><ref id="zoi230256r41"><label>41</label><mixed-citation publication-type="webpage"><person-group><collab>Massachusetts Department of Public Health</collab></person-group>. <italic toggle="yes">Data Brief: Opioid-Related Overdose Deaths Among Massachusetts Residents.</italic> Vol 11. Commonwealth of Massachusetts, Dept of Public Health; <year>2019</year>. Accessed March 7, 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mass.gov/doc/opioid-related-overdose-deaths-among-ma-residents-june-2020/download" ext-link-type="uri">https://www.mass.gov/doc/opioid-related-overdose-deaths-among-ma-residents-june-2020/download</ext-link></mixed-citation></ref><ref id="zoi230256r42"><label>42</label><mixed-citation publication-type="webpage"><person-group><collab>Centers for Disease Control and Prevention</collab></person-group>. <article-title>HIV infection, risk, prevention, and testing behaviors among persons who inject drugs&#8212;national HIV behavioral surveillance: injection drug use, 20 U.S. cities</article-title>, <year>2015</year>. Accessed January 1, 2020. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html" ext-link-type="uri">https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html</ext-link></mixed-citation></ref><ref id="zoi230256r43"><label>43</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Cedarbaum</surname><given-names>ER</given-names></string-name>, <string-name name-style="western"><surname>Banta-Green</surname><given-names>CJ</given-names></string-name></person-group>. <article-title>Health behaviors of young adult heroin injectors in the Seattle area</article-title>. <source>Drug Alcohol Depend</source>. <year>2016</year>;<volume>158</volume>:<fpage>102</fpage>-<lpage>109</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2015.11.011</pub-id><pub-id pub-id-type="pmid">26651427</pub-id></mixed-citation></ref><ref id="zoi230256r44"><label>44</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Hudgins</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>McCusker</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Stoddard</surname><given-names>A</given-names></string-name></person-group>. <article-title>Cocaine use and risky injection and sexual behaviors</article-title>. <source>Drug Alcohol Depend</source>. <year>1995</year>;<volume>37</volume>(<issue>1</issue>):<fpage>7</fpage>-<lpage>14</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0376-8716(94)01060-X</pub-id><pub-id pub-id-type="pmid">7882875</pub-id></mixed-citation></ref><ref id="zoi230256r45"><label>45</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Hser</surname><given-names>YI</given-names></string-name>, <string-name name-style="western"><surname>Mooney</surname><given-names>LJ</given-names></string-name>, <string-name name-style="western"><surname>Saxon</surname><given-names>AJ</given-names></string-name>, <etal/></person-group>. <article-title>High mortality among patients with opioid use disorder in a large healthcare system</article-title>. <source>J Addict Med</source>. <year>2017</year>;<volume>11</volume>(<issue>4</issue>):<fpage>315</fpage>-<lpage>319</lpage>. doi:<pub-id pub-id-type="doi">10.1097/ADM.0000000000000312</pub-id><pub-id pub-id-type="pmid">28426439</pub-id><pub-id pub-id-type="pmcid">PMC5930020</pub-id></mixed-citation></ref><ref id="zoi230256r46"><label>46</label><mixed-citation publication-type="book"><person-group><string-name name-style="western"><surname>Hedegaard</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Mini&#241;o</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Warner</surname><given-names>M</given-names></string-name></person-group>. <source>Drug Overdose Deaths in the United States, 1999&#8211;2017. </source>National Center for Health Statistics Data Brief 329. <publisher-name>National Center for Health Statistics</publisher-name>; <year>2018</year>.</mixed-citation></ref><ref id="zoi230256r47"><label>47</label><mixed-citation publication-type="webpage">Massachusetts Department of Public Health. An Assessment of Fatal and Nonfatal Opioid Overdoses in Massachusetts (2011-2015). Commonwealth of Massachusetts, Dept of Public Health; <fpage>2017</fpage>. Accessed March 7, 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mass.gov/doc/legislative-report-chapter-55-opioid-overdose-study-august-2017/download" ext-link-type="uri">https://www.mass.gov/doc/legislative-report-chapter-55-opioid-overdose-study-august-2017/download</ext-link></mixed-citation></ref><ref id="zoi230256r48"><label>48</label><mixed-citation publication-type="webpage"><person-group><collab>Massachusetts Department of Public Health</collab></person-group>. <italic toggle="yes">Data Brief: Opioid-Related Overdose Deaths among Massachusetts Residents</italic>. Commonwealth of Massachusetts, Dept of Public Health; <year>2019</year>. Accessed March 7, 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://archives.lib.state.ma.us/bitstream/handle/2452/802477/ocn951537951-2019-05.pdf?sequence=1&amp;isAllowed=y" ext-link-type="uri">https://archives.lib.state.ma.us/bitstream/handle/2452/802477/ocn951537951-2019-05.pdf?sequence=1&amp;isAllowed=y</ext-link></mixed-citation></ref><ref id="zoi230256r49"><label>49</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Caudarella</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Dong</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Milloy</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Kerr</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Wood</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Hayashi</surname><given-names>K</given-names></string-name></person-group>. <article-title>Non-fatal overdose as a risk factor for subsequent fatal overdose among people who inject drugs</article-title>. <source>Drug Alcohol Depend</source>. <year>2016</year>;<volume>162</volume>:<fpage>51</fpage>-<lpage>55</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2016.02.024</pub-id><pub-id pub-id-type="pmid">26993373</pub-id><pub-id pub-id-type="pmcid">PMC4833586</pub-id></mixed-citation></ref><ref id="zoi230256r50"><label>50</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Alagna</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>LP</given-names></string-name>, <string-name name-style="western"><surname>Nicholson</surname><given-names>BP</given-names></string-name>, <etal/></person-group>. <article-title>Repeat endocarditis: analysis of risk factors based on the International Collaboration on Endocarditis&#8212;prospective cohort study</article-title>. <source>Clin Microbiol Infect</source>. <year>2014</year>;<volume>20</volume>(<issue>6</issue>):<fpage>566</fpage>-<lpage>575</lpage>. doi:<pub-id pub-id-type="doi">10.1111/1469-0691.12395</pub-id><pub-id pub-id-type="pmid">24102907</pub-id></mixed-citation></ref><ref id="zoi230256r51"><label>51</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Miller</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Polgreen</surname><given-names>PM</given-names></string-name></person-group>. <article-title>Many opportunities to record, diagnose, or treat injection drug-related infections are missed: a population-based cohort study of inpatient and emergency department settings</article-title>. <source>Clin Infect Dis</source>. <year>2019</year>;<volume>68</volume>(<issue>7</issue>):<fpage>1166</fpage>-<lpage>1175</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/ciy632</pub-id><pub-id pub-id-type="pmid">30215683</pub-id></mixed-citation></ref><ref id="zoi230256r52"><label>52</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Meisner</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Anesi</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Grande</surname><given-names>D</given-names></string-name></person-group>. <article-title>Changes in infective endocarditis admissions in Pennsylvania during the opioid epidemic</article-title>. <source>Clin Infect Dis</source>. <year>2020</year>;<volume>71</volume>(<issue>7</issue>):<fpage>1664</fpage>-<lpage>1670</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/ciz1038</pub-id><pub-id pub-id-type="pmid">31630192</pub-id><pub-id pub-id-type="pmcid">PMC8241215</pub-id></mixed-citation></ref><ref id="zoi230256r53"><label>53</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Kimmel</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>J-H</given-names></string-name>, <string-name name-style="western"><surname>Kalesan</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Samet</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Walley</surname><given-names>AY</given-names></string-name>, <string-name name-style="western"><surname>Larochelle</surname><given-names>MR</given-names></string-name></person-group>. <article-title>Against medical advice discharges in injection and non-injection drug use-associated infective endocarditis: a nationwide cohort study</article-title>. <source>Clin Infect Dis</source>. <year>2021</year>;<volume>73</volume>(<issue>9</issue>):<fpage>e2484</fpage>-<lpage>e2492</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/ciaa1126</pub-id><pub-id pub-id-type="pmid">32756935</pub-id><pub-id pub-id-type="pmcid">PMC8563193</pub-id></mixed-citation></ref><ref id="zoi230256r54"><label>54</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Hall</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Le</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Majmudar</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Teesson</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mihalopoulos</surname><given-names>C</given-names></string-name></person-group>. <article-title>Treatment-seeking behaviour among people with opioid use disorder in the high-income countries: a systematic review and meta-analysis</article-title>. <source>PLoS One</source>. <year>2021</year>;<volume>16</volume>(<issue>10</issue>):<elocation-id>e0258620</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0258620</pub-id><pub-id pub-id-type="pmid">34653220</pub-id><pub-id pub-id-type="pmcid">PMC8519451</pub-id></mixed-citation></ref><ref id="zoi230256r55"><label>55</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Lewer</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Freer</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>King</surname><given-names>E</given-names></string-name>, <etal/></person-group>. <article-title>Frequency of health-care utilization by adults who use illicit drugs: a systematic review and meta-analysis</article-title>. <source>Addiction</source>. <year>2020</year>;<volume>115</volume>(<issue>6</issue>):<fpage>1011</fpage>-<lpage>1023</lpage>. doi:<pub-id pub-id-type="doi">10.1111/add.14892</pub-id><pub-id pub-id-type="pmid">31705770</pub-id><pub-id pub-id-type="pmcid">PMC7210080</pub-id></mixed-citation></ref><ref id="zoi230256r56"><label>56</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Sohler</surname><given-names>NL</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Kunins</surname><given-names>HV</given-names></string-name>, <etal/></person-group>. <article-title>Home- versus office-based buprenorphine inductions for opioid-dependent patients</article-title>. <source>J Subst Abuse Treat</source>. <year>2010</year>;<volume>38</volume>(<issue>2</issue>):<fpage>153</fpage>-<lpage>159</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jsat.2009.08.001</pub-id><pub-id pub-id-type="pmid">19801178</pub-id><pub-id pub-id-type="pmcid">PMC2849656</pub-id></mixed-citation></ref><ref id="zoi230256r57"><label>57</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Arias</surname><given-names>E</given-names></string-name></person-group>. <article-title>United States life tables, 2008</article-title>. <source>Natl Vital Stat Rep</source>. <year>2012</year>;<volume>61</volume>(<issue>3</issue>):<fpage>1</fpage>-<lpage>63</lpage>.<pub-id pub-id-type="pmid">24974590</pub-id></mixed-citation></ref><ref id="zoi230256r58"><label>58</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Chang</surname><given-names>KC</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Saxon</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Matthews</surname><given-names>AG</given-names></string-name>, <string-name name-style="western"><surname>Woody</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Hser</surname><given-names>YI</given-names></string-name></person-group>. <article-title>Causes of death and expected years of life lost among treated opioid-dependent individuals in the United States and Taiwan</article-title>. <source>Int J Drug Policy</source>. <year>2017</year>;<volume>43</volume>:<fpage>1</fpage>-<lpage>6</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drugpo.2016.12.003</pub-id><pub-id pub-id-type="pmid">28160734</pub-id><pub-id pub-id-type="pmcid">PMC5420493</pub-id></mixed-citation></ref><ref id="zoi230256r59"><label>59</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Verhagen</surname><given-names>DW</given-names></string-name>, <string-name name-style="western"><surname>Vedder</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Speelman</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>van der Meer</surname><given-names>JT</given-names></string-name></person-group>. <article-title>Antimicrobial treatment of infective endocarditis caused by viridans streptococci highly susceptible to penicillin: historic overview and future considerations</article-title>. <source>J Antimicrob Chemother</source>. <year>2006</year>;<volume>57</volume>(<issue>5</issue>):<fpage>819</fpage>-<lpage>824</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jac/dkl087</pub-id><pub-id pub-id-type="pmid">16549513</pub-id></mixed-citation></ref><ref id="zoi230256r60"><label>60</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Veldhuizen</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Callaghan</surname><given-names>RC</given-names></string-name></person-group>. <article-title>Cause-specific mortality among people previously hospitalized with opioid-related conditions: a retrospective cohort study</article-title>. <source>Ann Epidemiol</source>. <year>2014</year>;<volume>24</volume>(<issue>8</issue>):<fpage>620</fpage>-<lpage>624</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.annepidem.2014.06.001</pub-id><pub-id pub-id-type="pmid">25084705</pub-id></mixed-citation></ref><ref id="zoi230256r61"><label>61</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Rodger</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Glockler-Lauf</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Shojaei</surname><given-names>E</given-names></string-name>, <etal/></person-group>. <article-title>Clinical characteristics and factors associated with mortality in first-episode infective endocarditis among persons who inject drugs</article-title>. <source>JAMA Netw Open</source>. <year>2018</year>;<volume>1</volume>(<issue>7</issue>):<elocation-id>e185220</elocation-id>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2018.5220</pub-id><pub-id pub-id-type="pmid">30646383</pub-id><pub-id pub-id-type="pmcid">PMC6324402</pub-id></mixed-citation></ref><ref id="zoi230256r62"><label>62</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Cresti</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Chiavarelli</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Scalese</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Epidemiological and mortality trends in infective endocarditis, a 17-year population-based prospective study</article-title>. <source>Cardiovasc Diagn Ther</source>. <year>2017</year>;<volume>7</volume>(<issue>1</issue>):<fpage>27</fpage>-<lpage>35</lpage>. doi:<pub-id pub-id-type="doi">10.21037/cdt.2016.08.09</pub-id><pub-id pub-id-type="pmid">28164010</pub-id><pub-id pub-id-type="pmcid">PMC5253443</pub-id></mixed-citation></ref><ref id="zoi230256r63"><label>63</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Hill</surname><given-names>EE</given-names></string-name>, <string-name name-style="western"><surname>Herijgers</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Claus</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Vanderschueren</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Herregods</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Peetermans</surname><given-names>WE</given-names></string-name></person-group>. <article-title>Infective endocarditis: changing epidemiology and predictors of 6-month mortality: a prospective cohort study</article-title>. <source>Eur Heart J</source>. <year>2007</year>;<volume>28</volume>(<issue>2</issue>):<fpage>196</fpage>-<lpage>203</lpage>. doi:<pub-id pub-id-type="doi">10.1093/eurheartj/ehl427</pub-id><pub-id pub-id-type="pmid">17158121</pub-id></mixed-citation></ref><ref id="zoi230256r64"><label>64</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Ternhag</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Cederstr&#246;m</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>T&#246;rner</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Westling</surname><given-names>K</given-names></string-name></person-group>. <article-title>A nationwide cohort study of mortality risk and long-term prognosis in infective endocarditis in Sweden</article-title>. <source>PLoS One</source>. <year>2013</year>;<volume>8</volume>(<issue>7</issue>):<elocation-id>e67519</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0067519</pub-id><pub-id pub-id-type="pmid">23861768</pub-id><pub-id pub-id-type="pmcid">PMC3704638</pub-id></mixed-citation></ref><ref id="zoi230256r65"><label>65</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>McDonald</surname><given-names>JV</given-names></string-name>, <string-name name-style="western"><surname>Koziol</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>McCormick</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Viner-Brown</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Alexander-Scott</surname><given-names>N</given-names></string-name></person-group>. <article-title>Can emergency department, hospital discharge, and death data be used to monitor burden of drug overdose in Rhode Island?</article-title><source>J Public Health Manag Pract</source>. <year>2017</year>;<volume>23</volume>(<issue>5</issue>):<fpage>499</fpage>-<lpage>506</lpage>. doi:<pub-id pub-id-type="doi">10.1097/PHH.0000000000000514</pub-id><pub-id pub-id-type="pmid">28009694</pub-id></mixed-citation></ref><ref id="zoi230256r66"><label>66</label><mixed-citation publication-type="webpage"><person-group><collab>Agency for Healthcare Research and Quality</collab></person-group>. Medical Expenditure Panel Survey. Accessed January 20, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.meps.ahrq.gov/mepsweb/" ext-link-type="uri">https://www.meps.ahrq.gov/mepsweb/</ext-link><pub-id pub-id-type="pmid">38416859</pub-id></mixed-citation></ref><ref id="zoi230256r67"><label>67</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Behrends</surname><given-names>CN</given-names></string-name>, <string-name name-style="western"><surname>Paone</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Nolan</surname><given-names>ML</given-names></string-name>, <etal/></person-group>. <article-title>Estimated impact of supervised injection facilities on overdose fatalities and healthcare costs in New York City</article-title>. <source>J Subst Abuse Treat</source>. <year>2019</year>;<volume>106</volume>:<fpage>79</fpage>-<lpage>88</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jsat.2019.08.010</pub-id><pub-id pub-id-type="pmid">31540615</pub-id></mixed-citation></ref><ref id="zoi230256r68"><label>68</label><mixed-citation publication-type="webpage"><person-group><collab>US Department of Veterans Affairs</collab></person-group>. Pharmaceutical pricing: VA National Acquisition Center (NAC) programs. Accessed January 20, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fss.va.gov/index.asp" ext-link-type="uri">https://www.fss.va.gov/index.asp</ext-link></mixed-citation></ref><ref id="zoi230256r69"><label>69</label><mixed-citation publication-type="webpage"><person-group><collab>Centers for Medicare &amp; Medicaid Services</collab></person-group>. Physician Fee Schedule. Accessed January 20, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cms.gov/medicaremedicare-fee-service-paymentclinicallabfeeschedclinical-laboratory-fee-schedule-files/22clabq1" ext-link-type="uri">https://www.cms.gov/medicaremedicare-fee-service-paymentclinicallabfeeschedclinical-laboratory-fee-schedule-files/22clabq1</ext-link></mixed-citation></ref><ref id="zoi230256r70"><label>70</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Stein</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Phillips</surname><given-names>KT</given-names></string-name>, <string-name name-style="western"><surname>Herman</surname><given-names>DS</given-names></string-name>, <etal/></person-group>. <article-title>Skin-cleaning among hospitalized people who inject drugs: a randomized controlled trial</article-title>. <source>Addiction</source>. <year>2021</year>;<volume>116</volume>(<issue>5</issue>):<fpage>1122</fpage>-<lpage>1130</lpage>. doi:<pub-id pub-id-type="doi">10.1111/add.15236</pub-id><pub-id pub-id-type="pmid">32830383</pub-id></mixed-citation></ref><ref id="zoi230256r71"><label>71</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Jackson</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Bohm</surname><given-names>MK</given-names></string-name>, <string-name name-style="western"><surname>Brooks</surname><given-names>JT</given-names></string-name>, <etal/></person-group>. <article-title>Invasive methicillin-resistant staphylococcus aureus infections among persons who inject drugs&#8212;six sites, 2005-2016</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <year>2018</year>;<volume>67</volume>(<issue>22</issue>):<fpage>625</fpage>-<lpage>628</lpage>. doi:<pub-id pub-id-type="doi">10.15585/mmwr.mm6722a2</pub-id><pub-id pub-id-type="pmid">29879096</pub-id><pub-id pub-id-type="pmcid">PMC5991809</pub-id></mixed-citation></ref><ref id="zoi230256r72"><label>72</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Larney</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Peacock</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mathers</surname><given-names>BM</given-names></string-name>, <string-name name-style="western"><surname>Hickman</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Degenhardt</surname><given-names>L</given-names></string-name></person-group>. <article-title>A systematic review of injecting-related injury and disease among people who inject drugs</article-title>. <source>Drug Alcohol Depend</source>. <year>2017</year>;<volume>171</volume>:<fpage>39</fpage>-<lpage>49</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2016.11.029</pub-id><pub-id pub-id-type="pmid">28013096</pub-id></mixed-citation></ref><ref id="zoi230256r73"><label>73</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Kadri</surname><given-names>AN</given-names></string-name>, <string-name name-style="western"><surname>Wilner</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Hernandez</surname><given-names>AV</given-names></string-name>, <etal/></person-group>. <article-title>Geographic trends, patient characteristics, and outcomes of infective endocarditis associated with drug abuse in the United States from 2002 to 2016</article-title>. <source>J Am Heart Assoc</source>. <year>2019</year>;<volume>8</volume>(<issue>19</issue>):<elocation-id>e012969</elocation-id>. doi:<pub-id pub-id-type="doi">10.1161/JAHA.119.012969</pub-id><pub-id pub-id-type="pmid">31530066</pub-id><pub-id pub-id-type="pmcid">PMC6806029</pub-id></mixed-citation></ref><ref id="zoi230256r74"><label>74</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Kendall</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Boucher</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Donelle</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Engagement in primary health care among marginalized people who use drugs in Ottawa, Canada</article-title>. <source>BMC Health Serv Res</source>. <year>2020</year>;<volume>20</volume>(<issue>1</issue>):<fpage>837</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12913-020-05670-z</pub-id><pub-id pub-id-type="pmid">32894114</pub-id><pub-id pub-id-type="pmcid">PMC7487534</pub-id></mixed-citation></ref><ref id="zoi230256r75"><label>75</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Ker</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hsu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Balani</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Factors that affect patient attrition in buprenorphine treatment for opioid use disorder: a retrospective real-world study using electronic health records</article-title>. <source>Neuropsychiatr Dis Treat</source>. <year>2021</year>;<volume>17</volume>:<fpage>3229</fpage>-<lpage>3244</lpage>. doi:<pub-id pub-id-type="doi">10.2147/NDT.S331442</pub-id><pub-id pub-id-type="pmid">34737569</pub-id><pub-id pub-id-type="pmcid">PMC8560173</pub-id></mixed-citation></ref><ref id="zoi230256r76"><label>76</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Friedman</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Syvertsen</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Bourgois</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Bui</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Beletsky</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Pollini</surname><given-names>R</given-names></string-name></person-group>. <article-title>Intersectional structural vulnerability to abusive policing among people who inject drugs: a mixed methods assessment in California&#8217;s central valley</article-title>. <source>Int J Drug Policy</source>. <year>2021</year>;<volume>87</volume>:<elocation-id>102981</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.drugpo.2020.102981</pub-id><pub-id pub-id-type="pmid">33129133</pub-id><pub-id pub-id-type="pmcid">PMC7940555</pub-id></mixed-citation></ref><ref id="zoi230256r77"><label>77</label><mixed-citation publication-type="webpage"><person-group><collab>Agency for Healthcare Research and Quality</collab></person-group>. Medical Expenditure Panel Survey. Accessed January 20, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://meps.ahrq.gov/mepsweb" ext-link-type="uri">https://meps.ahrq.gov/mepsweb</ext-link><pub-id pub-id-type="pmid">38416859</pub-id></mixed-citation></ref><ref id="zoi230256r78"><label>78</label><mixed-citation publication-type="webpage"><person-group><collab>Process to Obtain Buprenorphine Waiver on DEA License</collab></person-group>. Accessed February 28, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://chcams.org/wp-content/uploads/2018/08/DATA-2000-Waiver-Process.pdf" ext-link-type="uri">https://chcams.org/wp-content/uploads/2018/08/DATA-2000-Waiver-Process.pdf</ext-link></mixed-citation></ref><ref id="zoi230256r79"><label>79</label><mixed-citation publication-type="webpage"><person-group><collab>Bureau of Labor Statistics, US Department of Labor</collab></person-group>. Occupational Outlook Handbook, Physicians and Surgeons. Accessed August 8, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.bls.gov/ooh/healthcare/physicians-and-surgeons.htm" ext-link-type="uri">https://www.bls.gov/ooh/healthcare/physicians-and-surgeons.htm</ext-link></mixed-citation></ref><ref id="zoi230256r80"><label>80</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Jones</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Kelley</surname><given-names>AT</given-names></string-name>, <string-name name-style="western"><surname>Suo</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>Trends in health service utilization after enrollment in an interdisciplinary primary care clinic for veterans with addiction, social determinants of health, or other vulnerabilities</article-title>. <source>J Gen Intern Med</source>. <year>2023</year>;<volume>38</volume>(<issue>1</issue>):<fpage>12</fpage>-<lpage>20</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11606-022-07456-x</pub-id><pub-id pub-id-type="pmid">35194740</pub-id><pub-id pub-id-type="pmcid">PMC8862702</pub-id></mixed-citation></ref><ref id="zoi230256r81"><label>81</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Wakeman</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Rigotti</surname><given-names>NA</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>Effect of integrating substance use disorder treatment into primary care on inpatient and emergency department utilization</article-title>. <source>J Gen Intern Med</source>. <year>2019</year>;<volume>34</volume>(<issue>6</issue>):<fpage>871</fpage>-<lpage>877</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11606-018-4807-x</pub-id><pub-id pub-id-type="pmid">30632103</pub-id><pub-id pub-id-type="pmcid">PMC6544728</pub-id></mixed-citation></ref><ref id="zoi230256r82"><label>82</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Gertner</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Robertson</surname><given-names>AG</given-names></string-name>, <string-name name-style="western"><surname>Powell</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Silberman</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Domino</surname><given-names>ME</given-names></string-name></person-group>. <article-title>Primary care providers and specialists deliver comparable buprenorphine treatment quality</article-title>. <source>Health Aff (Millwood)</source>. <year>2020</year>;<volume>39</volume>(<issue>8</issue>):<fpage>1395</fpage>-<lpage>1404</lpage>. doi:<pub-id pub-id-type="doi">10.1377/hlthaff.2019.01559</pub-id><pub-id pub-id-type="pmid">32744950</pub-id><pub-id pub-id-type="pmcid">PMC7895292</pub-id></mixed-citation></ref><ref id="zoi230256r83"><label>83</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Tsui</surname><given-names>JI</given-names></string-name>, <string-name name-style="western"><surname>Burt</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Thiede</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Glick</surname><given-names>SN</given-names></string-name></person-group>. <article-title>Utilization of buprenorphine and methadone among opioid users who inject drugs</article-title>. <source>Subst Abus</source>. <year>2018</year>;<volume>39</volume>(<issue>1</issue>):<fpage>83</fpage>-<lpage>88</lpage>. doi:<pub-id pub-id-type="doi">10.1080/08897077.2017.1363844</pub-id><pub-id pub-id-type="pmid">28796591</pub-id><pub-id pub-id-type="pmcid">PMC6467071</pub-id></mixed-citation></ref><ref id="zoi230256r84"><label>84</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Morgan</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Quinn</surname><given-names>EK</given-names></string-name>, <string-name name-style="western"><surname>Chaisson</surname><given-names>CE</given-names></string-name>, <etal/></person-group>. <article-title>Potential barriers to filling buprenorphine and naltrexone prescriptions among a retrospective cohort of individuals with opioid use disorder</article-title>. <source>J Subst Abuse Treat</source>. <year>2022</year>;<volume>133</volume>:<elocation-id>108540</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.jsat.2021.108540</pub-id><pub-id pub-id-type="pmid">34148756</pub-id><pub-id pub-id-type="pmcid">PMC8693788</pub-id></mixed-citation></ref><ref id="zoi230256r85"><label>85</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Schoenfeld</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Westafer</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Beck</surname><given-names>SA</given-names></string-name>, <etal/></person-group>. <article-title>&#8220;Just give them a choice&#8221;: patients&#8217; perspectives on starting medications for opioid use disorder in the ED</article-title>. <source>Acad Emerg Med</source>. <year>2022</year>;<volume>29</volume>(<issue>8</issue>):<fpage>928</fpage>-<lpage>943</lpage>. doi:<pub-id pub-id-type="doi">10.1111/acem.14507</pub-id><pub-id pub-id-type="pmid">35426962</pub-id><pub-id pub-id-type="pmcid">PMC9378535</pub-id></mixed-citation></ref><ref id="zoi230256r86"><label>86</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Weiss</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Egan</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Botsko</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Netherland</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Fiellin</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Finkelstein</surname><given-names>R</given-names></string-name></person-group>. <article-title>The BHIVES collaborative: organization and evaluation of a multisite demonstration of integrated buprenorphine/naloxone and HIV treatment</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2011</year>;<volume>56</volume>(<issue>suppl 1</issue>):<fpage>S7</fpage>-<lpage>S13</lpage>. doi:<pub-id pub-id-type="doi">10.1097/QAI.0b013e3182097426</pub-id><pub-id pub-id-type="pmid">21317598</pub-id></mixed-citation></ref><ref id="zoi230256r87"><label>87</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Hawk</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Coulter</surname><given-names>RWS</given-names></string-name>, <string-name name-style="western"><surname>Egan</surname><given-names>JE</given-names></string-name>, <etal/></person-group>. <article-title>Harm reduction principles for healthcare settings</article-title>. <source>Harm Reduct J</source>. <year>2017</year>;<volume>14</volume>(<issue>1</issue>):<fpage>70</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12954-017-0196-4</pub-id><pub-id pub-id-type="pmid">29065896</pub-id><pub-id pub-id-type="pmcid">PMC5655864</pub-id></mixed-citation></ref><ref id="zoi230256r88"><label>88</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Schackman</surname><given-names>BR</given-names></string-name>, <string-name name-style="western"><surname>Leff</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Polsky</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Moore</surname><given-names>BA</given-names></string-name>, <string-name name-style="western"><surname>Fiellin</surname><given-names>DA</given-names></string-name></person-group>. <article-title>Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care</article-title>. <source>J Gen Intern Med</source>. <year>2012</year>;<volume>27</volume>(<issue>6</issue>):<fpage>669</fpage>-<lpage>676</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11606-011-1962-8</pub-id><pub-id pub-id-type="pmid">22215271</pub-id><pub-id pub-id-type="pmcid">PMC3358393</pub-id></mixed-citation></ref><ref id="zoi230256r89"><label>89</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Murphy</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>McCollister</surname><given-names>KE</given-names></string-name>, <string-name name-style="western"><surname>Leff</surname><given-names>JA</given-names></string-name>, <etal/></person-group>. <article-title>Cost-effectiveness of buprenorphine-naloxone versus extended-release naltrexone to prevent opioid relapse</article-title>. <source>Ann Intern Med</source>. <year>2019</year>;<volume>170</volume>(<issue>2</issue>):<fpage>90</fpage>-<lpage>98</lpage>. doi:<pub-id pub-id-type="doi">10.7326/M18-0227</pub-id><pub-id pub-id-type="pmid">30557443</pub-id><pub-id pub-id-type="pmcid">PMC6581635</pub-id></mixed-citation></ref><ref id="zoi230256r90"><label>90</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Saloner</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Andraka Christou</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Gordon</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Stein</surname><given-names>BD</given-names></string-name></person-group>. <article-title>It will end in tiers: a strategy to include &#8220;dabblers&#8221; in the buprenorphine workforce after the X-waiver</article-title>. <source>Subst Abus</source>. <year>2021</year>;<volume>42</volume>(<issue>2</issue>):<fpage>153</fpage>-<lpage>157</lpage>. doi:<pub-id pub-id-type="doi">10.1080/08897077.2021.1903659</pub-id><pub-id pub-id-type="pmid">33798034</pub-id><pub-id pub-id-type="pmcid">PMC8667660</pub-id></mixed-citation></ref><ref id="zoi230256r91"><label>91</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Hsu</surname><given-names>YJ</given-names></string-name>, <string-name name-style="western"><surname>Marsteller</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Kachur</surname><given-names>SG</given-names></string-name>, <string-name name-style="western"><surname>Fingerhood</surname><given-names>MI</given-names></string-name></person-group>. <article-title>Integration of buprenorphine treatment with primary care: comparative effectiveness on retention, utilization, and cost</article-title>. <source>Popul Health Manag</source>. <year>2019</year>;<volume>22</volume>(<issue>4</issue>):<fpage>292</fpage>-<lpage>299</lpage>. doi:<pub-id pub-id-type="doi">10.1089/pop.2018.0163</pub-id><pub-id pub-id-type="pmid">30543495</pub-id></mixed-citation></ref><ref id="zoi230256r92"><label>92</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Rowe</surname><given-names>TA</given-names></string-name>, <string-name name-style="western"><surname>Jacapraro</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Rastegar</surname><given-names>DA</given-names></string-name></person-group>. <article-title>Entry into primary care-based buprenorphine treatment is associated with identification and treatment of other chronic medical problems</article-title>. <source>Addict Sci Clin Pract</source>. <year>2012</year>;<volume>7</volume>(<issue>1</issue>):<fpage>22</fpage>. doi:<pub-id pub-id-type="doi">10.1186/1940-0640-7-22</pub-id><pub-id pub-id-type="pmid">23186008</pub-id><pub-id pub-id-type="pmcid">PMC3509402</pub-id></mixed-citation></ref></ref-list><notes notes-type="supplementary-material" id="note-ZOI230256-1"><supplementary-material id="note-ZOI230256-1-s" position="float" content-type="local-data" orientation="portrait"><label>Supplement 1.</label><caption><p><bold>eMethods.</bold> Supplemental Methods</p><p><bold>eTable 1.</bold> Calibration Targets</p><p><bold>eTable 2.</bold> Cost-effectiveness of Integrated Addiction Services Into Primary Care Assuming Lower Probability of PDD Discharge Rate</p><p><bold>eTable 3.</bold> Cost-effectiveness of Integrated Addiction Services Into Primary Care Assuming Higher Probability of PDD Discharge Rate</p><p><bold>eTable 4.</bold> Cost-effectiveness of Integrated Addiction Services Into Primary Care Assuming a Lower Probability of Spontaneous &#8220;Unlinkage&#8221; From Outpatient Addiction Without MOUD</p><p><bold>eTable 5.</bold> Cost-effectiveness of Integrated Addiction Services Into Primary Care Assuming Higher Probability of Spontaneous &#8220;Unlinkage&#8221; From Outpatient Addiction Without MOUD</p><p><bold>eTable 6.</bold> Cost-effectiveness of Integrated Addiction Services Into Primary Care Assuming a Lower Probability of Hospitalization for Overdose</p><p><bold>eTable 7.</bold> Cost-effectiveness of Integrated Addiction Services Into Primary Care Assuming a Higher Probability of Hospitalization for Overdose</p><p><bold>eTable 8.</bold> Cost-effectiveness of Integrated Addiction Services Into Primary Care Assuming a Lower Probability of Inpatient Linkage</p><p><bold>eTable 9.</bold> Cost-effectiveness of Integrated Addiction Services Into Primary Care Assuming a Higher Probability of Inpatient Linkage</p><p><bold>eTable 10.</bold> Cost-effectiveness of Integrated Addiction Services Into Primary Care Assuming a Lower Probability of Fatal Overdose </p><p><bold>eTable 11.</bold> Cost-effectiveness of Integrated Addiction Services Into Primary Care Assuming a Higher Probability of Fatal Overdose</p><p><bold>eTable 12.</bold> Cost-effectiveness of Integrated Addiction Services Into Primary Care Assuming a Lower Probability Spontaneous &#8220;Unlinkage&#8221; From Outpatient Addiction With MOUD</p><p><bold>eTable 13.</bold> Cost-effectiveness of Integrated Addiction Services Into Primary Care Assuming a Higher Probability of Spontaneous &#8220;Unlinkage&#8221; From Outpatient Addiction With MOUD</p><p><bold>eTable 14.</bold> Cost-effectiveness of Integrated Addiction Services Into Primary Care Assuming a Lower Inpatient MOUD Cost</p><p><bold>eTable 15.</bold> Cost-effectiveness of Integrated Addiction Services Into Primary Care Assuming a Higher Inpatient MOUD Cost</p><p><bold>eTable 16.</bold> Cost-effectiveness of Integrated Addiction Services Into Primary Care Assuming a Lower Previous Infection Multiplier for Risk of Subsequent Infection</p><p><bold>eTable 17.</bold> Cost-effectiveness of Integrated Addiction Services Into Primary Care Assuming a Higher Previous Infection Multiplier for Risk of Subsequent Infection</p><p><bold>eTable 18.</bold> Cost-effectiveness of Integrated Addiction Services Into Primary Care Assuming a Lower Probability of Background or Inpatient Linkage of Outpatient Addiction Care</p><p><bold>eTable 19.</bold> Cost-effectiveness of Integrated Addiction Services Into Primary Care Assuming a Higher Probability of Background or Inpatient Linkage of Outpatient Addiction Care</p><p><bold>eTable 20.</bold> Cost-effectiveness of Integrated Addiction Services Into Primary Care Assuming Lower Probability of Needle Sharing</p><p><bold>eTable 21.</bold> Cost-effectiveness of Integrated Addiction Services Into Primary Care Assuming a Higher Probability of Needle Sharing</p><p><bold>eTable 22.</bold> Cost-effectiveness of Integrated Addiction Services Into Primary Care Assuming a Lower Probability of Death, Inpatient With SSTI</p><p><bold>eTable 23.</bold> Cost-effectiveness of Integrated Addiction Services Into Primary Care Assuming a Higher Probability of Death, Inpatient With SSTI</p><p><bold>eTable 24.</bold> Cost-effectiveness of Integrated Addiction Services Into Primary Care Assuming a Lower Probability of Hospitalization For SSTI</p><p><bold>eTable 25.</bold> Cost-effectiveness of Integrated Addiction Services Into Primary Care Assuming a Higher Probability of Hospitalization for SSTI</p><p><bold>eTable 26.</bold> Cost-effectiveness of Integrated Addiction Services Into Primary Care Assuming a Lower Probability of Hospitalization for IE</p><p><bold>eTable 27.</bold> Cost-effectiveness of Integrated Addiction Services Into Primary Care Assuming a Higher Probability of Hospitalization for IE</p><p><bold>eTable 28.</bold> Cost-effectiveness of Integrated Addiction Services Into Primary Care Assuming Lower Cost of Untreated Non-Fatal Overdose</p><p><bold>eTable 29.</bold> Cost-effectiveness of Integrated Addiction Services Into Primary Care Assuming a Higher Cost of Untreated Non-Fatal Overdose</p><p><bold>eTable 30.</bold> Cost-effectiveness of Integrated Addiction Services Into Primary Care Assuming a Lower Fatal Overdose Cost</p><p><bold>eTable 31.</bold> Cost-effectiveness of Integrated Addiction Services Into Primary Care Assuming Higher Fatal Overdose Cost</p><p><bold>eTable 32.</bold> Cost-effectiveness of Integrated Addiction Services Into Primary Care Assuming a Lower Probability of Death From Untreated SSTI </p><p><bold>eTable 33.</bold> Cost-effectiveness of Integrated Addiction Services Into Primary Care Assuming a Higher Probability of Death From Untreated SSTI</p><p><bold>eTable 34.</bold> Cost-effectiveness of Integrated Addiction Services Into Primary Care Assuming a Lower Probability of Death From Untreated IE</p><p><bold>eTable 35.</bold> Cost-effectiveness of Integrated Addiction Services Into Primary Care Assuming a Higher Probability of Death From Untreated IE</p><p><bold>eTable 36.</bold> Cost-effectiveness of Integrated Addiction Services Into Primary Care Assuming a Lower Cost of Outpatient Addiction Visit With MOUD</p><p><bold>eTable 37.</bold> Cost-effectiveness of Integrated Addiction Services Into Primary Care Assuming Higher Cost of Outpatient Addiction Visit With MOUD</p><p><bold>eTable 38.</bold> Cost-effectiveness of Integrated Addiction Services Into Primary Care Assuming a Lower Probability of Outpatient Addiction Care From Inpatient Care (No MOUD) Without ACS</p><p><bold>eTable 39.</bold> Cost-effectiveness of Integrated Addiction Services Into Primary Care Assuming a Higher Probability of Outpatient Addiction Care From Inpatient Care (No MOUD) Without ACS</p><p><bold>eTable 40.</bold> Cost-effectiveness of Integrated Addiction Services Into Primary Care Assuming a Lower Probability of Linkage to Outpatient Addiction Care (MOUD) From Inpatient Without ACS, With MOUD</p><p><bold>eTable 41.</bold> Cost-effectiveness of Integrated Addiction Services Into Primary Care Assuming a Higher Probability of Linkage to Outpatient Addiction Care (MOUD) From Inpatient Without ACS, With MOUD</p><p><bold>eTable 42.</bold> Model Parameters, Data Type Used to Inform Parameters, and Sampling Distributions for Probabilistic Sensitivity Analyses</p><p><bold>eTable 43.</bold> Model Outcomes and Credible Intervals for Status Quo, BUP, and BUP + HR</p><p><bold>eFigure 1.</bold> Lifetime Clinical Outcomes Cases Averted per 10,000 in BUP, BUP + HR Compared to Status Quo Strategies</p><p><bold>eFigure 2.</bold> Deterministic Sensitivity Analysis- Tornado Chart of BUP + HR versus SQ</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jamanetwopen-e237888-s001.pdf" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material position="float" content-type="local-data" orientation="portrait"><label>Supplement 2.</label><caption><p>
Data Sharing Statement
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jamanetwopen-e237888-s002.pdf" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></notes></back></article></pmc-articleset>